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Abstract: Over the past decades, allotransplantation has evolved from an experimental procedure to
a very successful, often life-saving therapy and has emerged as the best therapy to treat patients with
end-stage organ failure. The success of this surgical intervention has led to an increasing demand limited
by the availability of organs. To overcome the acute shortage of human organs, xenotransplantation has
become a focus of interest and a very important area of transplantation research. Miniature pigs have
evolved as the most suitable source of organs for several reasons including: housing in a pathogen-free
environment, the capacity to breed and have a big number of offspring and last but not least some
similarities shared with human organs regarding size and physiology. Currently, clinical pig-to-human
trials involving porcine islet cells are performed with encouraging results since patients have seen their
daily dose of insulin reduced and one of the patients is said to be insulin-free. However, because of
a high immunosuppression treatment to prevent graft rejection, the transplanted organ will inevitably
be in contact with pathogens. Concern has mainly been focused on donor-derived xenogeneic infection,
neglecting host-derived infection with their potentially severe consequences for the xenograft including
rejection and loss of function. Primary infection and reactivation of human cytomegalovirus (HCMV)
is the most important viral complication post- transplantation and has been associated with allograft
rejection. Our laboratory has previously demonstrated that HCMV cross-species infection of porcine
cells induces atypical cytopathic effect and induces apoptosis, which may eventually result in porcine
xenograft rejection. The goal of my thesis was to investigate potential HCMV entry pathways in porcine
endothelial cells, in order to develop strategies for prevention and to compare it with human endothelial
cells, yielding potentially new insights on the mechanisms of HCMV entry. My findings demonstrate
that similarly to entry into human cells, entry of both the endotheliotropic (TB40/E) and the fibrotropic
(TB40/F) (except for microvascular porcine endothelial cells) strains into porcine endothelial cells (pEC)
requires the expression of the ￿1 integrin subunit. In contrast, the expression of platelet-derived growth
factor receptor alpha (PDGFR￿) is required for entry of both strains in pEC only. I demonstrate that
internalization of TB40/E viral particles by human endothelial cells and pEC occurs with a similar mech-
anism, i.e. a dynamin-2-, lipid rafts-, actin- and pH-dependent mechanism, whereas internalization of
TB40/F viral particles by pEC occurs mainly by a dynamin-2-dependent, clathrin-, lipid rafts- inde-
pendent mechanism and in a pH dispensable manner. Besides, when actin polymerisation is prevented,
TB40/F enters pEC in an actin-independent fashion, suggesting an entry by fusion or the involvement
of another component of the cellular cytoskeleton. I demonstrate for the first time that after internal-
ization, TB40/E viral particles translocate to the nucleus of hEC through the classical endolysosomal
pathway going from early endosomes to late endosome / lysosomes. Similar results were observed for
pEC. In contrast, in TB40/F-infected hEC, viral particles located only in early endosome, suggesting a
sequestration of virions in this compartment, whereas in pEC, viral particles were able to transfer from
early endosomes to late endosomes / lysosomes. Finally, I demonstrate that nuclear translocation differs
between hEC and pEC and viral strains, as observed by a nuclear accumulation of the tegument protein
pp65 only in TB40/F-infected pEC. This differential nuclear accumulation is correlated with a higher ac-
cumulation of pp65 in TB40/F-infected EC compared to TB40/E-infected EC, which results in an earlier
initiation of replication of TB40/F compared to TB40/E in pEC. In conclusion, my findings suggest that
HCMV uses distinct entry pathways that are dependent on both the strain and the origin of the target
cells, underlying the capacity of HCMV to adapt to its environment, and its ability, following entry, to
induce a successful infection of pEC challenges the traditional paradigm of species specificity. Besides
its fundamental research significance, investigation of HCMV cross species infection has an important
implication when applied to xenotransplantation. Determining the early events of infection will help
in developing strategies to prevent HCMV infection by blocking entry into porcine cells or by rendering
swine resistant to HCMV infection, which is essential for xenotransplantation to become a clinical reality.
Die Allotransplantation hat sich von einem experimentellen Verfahren zu einer sehr erfolgreichen, häufig
lebensrettenden Behandlung von Patienten mit terminalem Organversagen entwickelt. Dieser Erfolg hat
zu einer zunehmenden Verknappung von Organen geführt. Als Alternative ist die Xenotransplantation
in den Blickpunkt des Interesses gerückt. Miniaturschweine werden als die aktuell besten Spender ange-
sehen, weil diese verschiedene Voraussetzungen erfüllen: Pathogen-freies Züchten und Halten der Tiere,
eine relative kurze Tragzeit und Nachkommen in genügender Anzahl. Weitere Vorteile sind eine ähn-
liche Physiologie und Grösse der Organe. Aktuell gibt es weltweit klinische Versuche mit Transplantation
porziner Inselzellen in Menschen zur Behandlung der Diabetes; diese Versuche sind vielversprechend. Für
die Organtransplantation ist davon auszugehen, dass für die Verhinderung der Abstossung eine erhebliche
immunsuppressive Therapie notwendig sein wird. Dabei steht das transplantierte Organ in engem Kon-
takt mit potentiellen Pathogenen. Bisher waren die Bedenken auf eine Uebertragung von vom Spender
ausgehenden Infektionen ausgerichtet, sog. xenogenen Infektionen. Dabei wurde zu wenig berücksichtigt,
dass humane Pathogene das transplantierte Organ ebenfalls befallen und schädigen können, mit dem
Resultat eines Organversagens. Die Infektion mit Zytomegalievirus spielt in diesem Zusammenhang eine
wichtige Rolle, ist sie doch die häufigste virale Komplikation nach Allotransplantation. Unser Labor
konnte in früheren Studien darlegen, dass menschliche Zytomegalieviren porzine Zellen infizieren können.
Diese Infektion führte zu Veränderungen des Phänotyps mit einer alterierten Expression verschiedener
Marker und zu zytopathischen Effekten und Induktion der Apoptose. Diese Veränderungen haben das
Potential, in einem transplantierten Organ eine Abstossung oder eine Funktionsverlust zu induzieren. Ziel
dieser Arbeit war es, die Mechanismen des Eindringens von Zytomegalieviren in porzine Endothelzellen
zu studieren. Ein besseres Verständnis würde es erlauben, Strategien zur Verhinderung einer solchen
Infektion zu entwickeln. Meine Resultate demonstrieren, dass wie im menschlichen Modell mit humanen
Endothelzellen sowohl endotheliotrope (TB40/E) als auch fibrotrope (TB40/F) Stämme für eine erfolgre-
iche Infektion den Korezeptor ￿1 Integrin benötigen. Auf der anderen Seite ist PDGFR￿ (platelet-derived
growth factor receptor alpha) notwendig in porzinen, nicht aber in humanen Zellen. Internalisierung
von TB40/E erfolgt sowohl in menschlichen als auch porzinen Zellen durch ähnliche Mechanismen, so
ist dieser Prozess Dynamin-2-, lipid rafts (Cholesterin-reiche Mikrodomänen in Zellmembranen)-, Aktin-
und pH-abhängig. Beim fibrotropen Stamm (TB40/F) erfolgt dieser Prozess in porzinen Zellen mittels
eines Dynamin-2- abhängigen, aber Clathrin-, lipid raft-unabhängigen Mechanismus, auch schient der
pH keine Rolle zu spielen. Aktin ist für das Eindringen von TB40/F in porzine Zellen nicht notwendig.
Ich konnte ebenfalls zum ersten Mal im menschlichen Modell zeigen, das TB40/E nach Eindringen den
klassischen endolysosomalen Weg zum Zellkern nimmt, und dass dies auch für porzine Zellen gilt. Ein
anderes Verhalten wies der fibrotrope Stamm TB40/F auf: In menschlichen Ednothelzellen konnte dieser
nur in einem frühen Lysosm nachgewiesen werden, während in porzinen Zellen der ganze Transportweg
nachverfolgt werden konnte. Mittels des Nachweises der Akkumulation eines viralen Tegumentproteins,
pp65, konnten wir nachweisen, dass der Transfer zum Nukleus differiert zwischen humanen und porzinen
Endothelzellen, was zu einer früheren und gesteigerten Replikation von TB40/F im Vergleich zu TB40/E
in porzinen Endothelzellen führt. Zusammenfassend zeigen meine Resultate auf, dass Zytomegalieviren
eine Vielzahl verschiedener Möglichkeiten aufweisen, Zellen zu infizieren. Dabei sind die Unterschiede
nicht primär zwischen Zellen verschiedener Arten sichtbar, sondern vielmehr abhängig von der jeweili-
gen anatomischen Abstammung der Zelle und vom Virusstamm. Diese Erkenntnisse zeigen die enorme
Adaptationsfähigkeit von Zytomegalieviren auf, sich in verschiedenen Zellen zu replizieren und infektions-
fähige Nachkommen zu generieren. Damit ist auch das lang-gehegte Paradigma der Spezies-Spezifität in
Frage gestellt. Diese Resultate haben neben der biologischen Bedeutung auch die praktische Konsequenz,
dass nach Transplantation eines porzinen Organs im Menschen mit einer Infektion durch humane Zy-
tomegalieviren gerechnet werden muss. Der Verhinderung einer solchen Infektion kommt dabei zentrale
Bedeutung zu, bevor Xenotransplantation eine klinische Realität wird.
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“In the end, everything will be ok. 
If it’s not ok, it’s not yet the end” 
Fernando Sabino 
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1 Summary 
Over the past decades, allotransplantation has evolved from an experimental 
procedure to a very successful, often life-saving therapy and has emerged as the best 
therapy to treat patients with end-stage organ failure. The success of this surgical 
intervention has led to an increasing demand limited by the availability of organs. To 
overcome the acute shortage of human organs, xenotransplantation has become a 
focus of interest and a very important area of transplantation research. Miniature pigs 
have evolved as the most suitable source of organs for several reasons including: 
housing in a pathogen-free environment, the capacity to breed and have a big number 
of offspring and last but not least some similarities shared with human organs 
regarding size and physiology. Currently, clinical pig-to-human trials involving 
porcine islet cells are performed with encouraging results since patients have seen 
their daily dose of insulin reduced and one of the patients is said to be insulin-free. 
However, because of a high immunosuppression treatment to prevent graft rejection, 
the transplanted organ will inevitably be in contact with pathogens. Concern has 
mainly been focused on donor-derived xenogeneic infection, neglecting host-derived 
infection with their potentially severe consequences for the xenograft including 
rejection and loss of function. Primary infection and reactivation of human 
cytomegalovirus (HCMV) is the most important viral complication post-
transplantation and has been associated with allograft rejection. Our laboratory has 
previously demonstrated that HCMV cross-species infection of porcine cells induces 
atypical cytopathic effect and induces apoptosis, which may eventually result in 
porcine xenograft rejection. The goal of my thesis was to investigate potential HCMV 
entry pathways in porcine endothelial cells, in order to develop strategies for 
prevention and to compare it with human endothelial cells, yielding potentially new 
insights on the mechanisms of HCMV entry.  
My findings demonstrate that similarly to entry into human cells, entry of both 
the endotheliotropic (TB40/E) and the fibrotropic (TB40/F) (except for microvascular 
porcine endothelial cells) strains into porcine endothelial cells (pEC) requires the 
expression of the β1 integrin subunit. In contrast, the expression of platelet-derived 
growth factor receptor alpha (PDGFRα) is required for entry of both strains in pEC 
only. I demonstrate that internalization of TB40/E viral particles by human 
Summary 
8 
endothelial cells and pEC occurs with a similar mechanism, i.e. a dynamin-2-, lipid 
rafts-, actin- and pH-dependent mechanism, whereas internalization of TB40/F viral 
particles by pEC occurs mainly by a dynamin-2-dependent, clathrin-, lipid rafts-
independent mechanism and in a pH dispensable manner. Besides, when actin 
polymerisation is prevented, TB40/F enters pEC in an actin-independent fashion, 
suggesting an entry by fusion or the involvement of another component of the cellular 
cytoskeleton. I demonstrate for the first time that after internalization, TB40/E viral 
particles translocate to the nucleus of hEC through the classical endolysosomal 
pathway going from early endosomes to late endosome / lysosomes. Similar results 
were observed for pEC. In contrast, in TB40/F-infected hEC, viral particles located 
only in early endosome, suggesting a sequestration of virions in this compartment, 
whereas in pEC, viral particles were able to transfer from early endosomes to late 
endosomes / lysosomes. Finally, I demonstrate that nuclear translocation differs 
between hEC and pEC and viral strains, as observed by a nuclear accumulation of the 
tegument protein pp65 only in TB40/F-infected pEC. This differential nuclear 
accumulation is correlated with a higher accumulation of pp65 in TB40/F-infected EC 
compared to TB40/E-infected EC, which results in an earlier initiation of replication 
of TB40/F compared to TB40/E in pEC. 
In conclusion, my findings suggest that HCMV uses distinct entry pathways 
that are dependent on both the strain and the origin of the target cells, underlying the 
capacity of HCMV to adapt to its environment, and its ability, following entry, to 
induce a successful infection of pEC challenges the traditional paradigm of species 
specificity. Besides its fundamental research significance, investigation of HCMV 
cross species infection has an important implication when applied to 
xenotransplantation. Determining the early events of infection will help in developing 
strategies to prevent HCMV infection by blocking entry into porcine cells or by 
rendering swine resistant to HCMV infection, which is essential for 
xenotransplantation to become a clinical reality. 
Zusammenfassung 
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2 Zusammenfassung 
Die Allotransplantation hat sich von einem experimentellen Verfahren zu einer 
sehr erfolgreichen, häufig lebensrettenden Behandlung von Patienten mit terminalem 
Organversagen entwickelt. Dieser Erfolg hat zu einer zunehmenden Verknappung von 
Organen geführt. Als Alternative ist die Xenotransplantation in den Blickpunkt des 
Interesses gerückt. Miniaturschweine werden als die aktuell besten Spender 
angesehen, weil diese verschiedene Voraussetzungen erfüllen: Pathogen-freies 
Züchten und Halten der Tiere, eine relative kurze Tragzeit und Nachkommen in 
genügender Anzahl. Weitere Vorteile sind eine ähnliche Physiologie und Grösse der 
Organe. Aktuell gibt es weltweit klinische Versuche mit Transplantation porziner 
Inselzellen in Menschen zur Behandlung der Diabetes; diese Versuche sind 
vielversprechend. Für die Organtransplantation ist davon auszugehen, dass für die 
Verhinderung der Abstossung eine erhebliche immunsuppressive Therapie notwendig 
sein wird. Dabei steht das transplantierte Organ in engem Kontakt mit potentiellen 
Pathogenen. Bisher waren die Bedenken auf eine Uebertragung von vom Spender 
ausgehenden Infektionen ausgerichtet, sog. xenogenen Infektionen. Dabei wurde zu 
wenig berücksichtigt, dass humane Pathogene das transplantierte Organ ebenfalls 
befallen und schädigen können, mit dem Resultat eines Organversagens. Die Infektion 
mit Zytomegalievirus spielt in diesem Zusammenhang eine wichtige Rolle, ist sie 
doch die häufigste virale Komplikation nach Allotransplantation. Unser Labor konnte 
in früheren Studien darlegen, dass menschliche Zytomegalieviren porzine Zellen 
infizieren können. Diese Infektion führte zu Veränderungen des Phänotyps mit einer 
alterierten Expression verschiedener Marker und zu zytopathischen Effekten und 
Induktion der Apoptose. Diese Veränderungen haben das Potential, in einem 
transplantierten Organ eine Abstossung oder eine Funktionsverlust zu induzieren.  
Ziel dieser Arbeit war es, die Mechanismen des Eindringens von 
Zytomegalieviren in porzine Endothelzellen zu studieren. Ein besseres Verständnis 
würde es erlauben, Strategien zur Verhinderung einer solchen Infektion zu 
entwickeln. 
Meine Resultate demonstrieren, dass wie im menschlichen Modell mit 
humanen Endothelzellen sowohl endotheliotrope (TB40/E) als auch fibrotrope 
(TB40/F) Stämme für eine erfolgreiche Infektion den Korezeptor β1 Integrin 
Zusammenfassung 
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benötigen. Auf der anderen Seite ist PDGFRα (platelet-derived growth factor receptor 
alpha) notwendig in porzinen, nicht aber in humanen Zellen. Internalisierung von 
TB40/E erfolgt sowohl in menschlichen als auch porzinen Zellen durch ähnliche 
Mechanismen, so ist dieser Prozess Dynamin-2-, lipid rafts (Cholesterin-reiche 
Mikrodomänen in Zellmembranen)-, Aktin- und pH-abhängig. Beim fibrotropen 
Stamm (TB40/F) erfolgt dieser Prozess in porzinen Zellen mittels eines Dynamin-2-
abhängigen, aber Clathrin-, lipid raft-unabhängigen Mechanismus, auch schient der 
pH keine Rolle zu spielen. Aktin ist für das Eindringen von TB40/F in porzine Zellen 
nicht notwendig. Ich konnte ebenfalls zum ersten Mal im menschlichen Modell 
zeigen, das TB40/E nach Eindringen den klassischen endolysosomalen Weg zum 
Zellkern nimmt, und dass dies auch für porzine Zellen gilt. Ein anderes Verhalten 
wies der fibrotrope Stamm TB40/F auf: In menschlichen Ednothelzellen konnte dieser 
nur in einem frühen Lysosm nachgewiesen werden, während in porzinen Zellen der 
ganze Transportweg nachverfolgt werden konnte. Mittels des Nachweises der 
Akkumulation eines viralen Tegumentproteins, pp65, konnten wir nachweisen, dass 
der Transfer zum Nukleus differiert zwischen humanen und porzinen Endothelzellen, 
was zu einer früheren und gesteigerten Replikation von TB40/F im Vergleich zu 
TB40/E in porzinen Endothelzellen führt.  
Zusammenfassend zeigen meine Resultate auf, dass Zytomegalieviren eine 
Vielzahl verschiedener Möglichkeiten aufweisen, Zellen zu infizieren. Dabei sind die 
Unterschiede nicht primär zwischen Zellen verschiedener Arten sichtbar, sondern 
vielmehr abhängig von der jeweiligen anatomischen Abstammung der Zelle und vom 
Virusstamm. Diese Erkenntnisse zeigen die enorme Adaptationsfähigkeit von 
Zytomegalieviren auf, sich in verschiedenen Zellen zu replizieren und 
infektionsfähige Nachkommen zu generieren. Damit ist auch das lang-gehegte 
Paradigma der Spezies-Spezifität in Frage gestellt. Diese Resultate haben neben der 
biologischen Bedeutung auch die praktische Konsequenz, dass nach Transplantation 
eines porzinen Organs im Menschen mit einer Infektion durch humane 
Zytomegalieviren gerechnet werden muss. Der Verhinderung einer solchen Infektion 
kommt dabei zentrale Bedeutung zu, bevor Xenotransplantation eine klinische 
Realität wird. 
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3 Introduction 
3.1 Discovery of human cytomegalovirus (HCMV) 
In 1881, German scientists described for the first time intranuclear inclusions 
in sections of the kidney of a stillborn infant with congenital syphilis and in the 
parotid gland of children (232). They attributed this discovery to protozoa after seeing 
a report from Jesionek and Kiolemenoglou describing similar cells as “protozoan 
like” cells in the lungs, kidneys and liver of a luetic foetus (136). In the 1920’s, Von 
Glahn and Pappenheimer suggested a viral etiology by linking these cellular 
abnormalities with intranuclear inclusion containing cells in lesions in man infected 
by herpes zoster and herpes genitalis (303). The isolation of the viral agent became 
possible only after human cells were routinely grown in cell culture. Three 
independent groups isolated the viral agent in the 1950’s. In 1955, Margaret Smith 
isolated a virus from the salivary gland of a dead patient that grew only in human cells 
but not in murine cells. Her paper was rejected because she was working in parallel 
with a murine salivary gland virus and a possible contamination was suspected. One 
year later her discovery was published after she re-isolated the same agent from 
another kidney from a patient (268). That same year, Rowe isolated the same agent 
from adenoid tissue of a child, and this strain was then referred to as AD169 (234). 
Finally, Weller isolated the virus from a patient suspected to have toxoplasmosis (58) 
and in 1960 he named it cytomegalovirus. 
 
Figure 1: Representation of cells with intranuclear inclusions suspected to be parasites as 
decribed by Jesionek and Kiolemenoglou (left) (136) or CMV-infected cytomegalic cells 
(right). 
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3.2 Epidemiology of HCMV infection 
3.2.1 Clinical relevance 
HCMV is observed in all geographic locations and socio-economic groups and 
infects 50-90% of the adult population. Seroprevalence increases with age (7) and is 
higher in developing countries and in communities with a low socio-economic status. 
Like all herpesviruses, HCMV establishes a life-long latent infection after primary 
infection. In immunocompetent hosts, primary infection is asymptomatic or induces a 
mononucleosis-like syndrome. However, in rare cases, HCMV infection can lead to 
severe illness involving different organs, resulting for instance in hepatitis, 
neuropathies, encephalitis, myocarditis and ocular disease (75, 159). By contrast, in 
immunocompromised individuals, including neonates, AIDS patients, and transplant 
recipients, HCMV infection often causes life-threatening diseases, including 
pneumonia, gastrointestinal disease, hepatitis, retinitis, and encephalitis, resulting in 
significant morbidity and increased mortality (49, 217, 228, 280). 
In human immunodeficiency virus (HIV) positive patients, HCMV is an 
important opportunistic pathogen. In advanced HIV diseases with low CD4 T helper 
cell numbers, CMV disease can reactivate, with retinitis being the most common 
clinical manifestation. Retinitis reduces the visual acuity and the damages are 
irreversible (250). If not treated, retinitis expands to both eyes and later HCMV 
spreads to other organs with the development of encephalitis. Since the introduction 
of antiretroviral therapy (ART), the incidence of HCMV retinitis has dramatically 
declined (67), and today, most cases of HCMV retinitis occur in patients where HIV 
is diagnosed late in the course of disease or who are unable to control the infection 
(no access to ART, etc.) 
Congenital HCMV infection remains an important public health problem 
causing significant morbidity and mortality. Primo-infection or infection with another 
strain occurring early in gestation can lead to spontaneous abortion (110). Although 
most neonates infected in utero do not show any signs of infection (204), 
complications may occur in the first year including hearing loss, mental retardation 
and visual abnormality (37, 157). When transmission occurs later in pregnancy, it is 
associated with premature delivery and intrauterine growth retardation (133). 
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HCMV infection is also involved in other diseases such as atherosclerosis 
(thickening of artery wall as a result of the accumulation of fatty materials such as 
cholesterol and triglyceride). HCMV infection stimulates cellular proliferation and 
increases angiogenesis (16). Several contradictory studies about the detection of 
HCMV in normal and atherosclerotic samples leave some doubts on the involvement 
of HCMV infection in atherosclerosis (318, 320). However, more recently, a survey 
demonstrated that CMV seropositivity and inflammation are associated with higher 
risk of cardiovascular disease-related death (260). 
Finally, in transplant recipients, HCMV is the most important viral infectious 
complication and is associated with allograft rejection. HCMV infection in solid 
organ transplant recipients often manifests by HCMV syndrome (fever, anorexia and 
malaise), and is often linked with dysfunction of the organ transplanted: hepatitis in 
liver recipients, pancreatitis after pancreas transplantation, myocarditis in heart 
recipients and pneumonitis in lung or lung and heart recipients (170). Indirect effects 
are also observed such as a decreased efficiency of the immune system leading to the 
development of opportunistic infections, and allograft rejection (170). 
3.2.2 Transmission of HCMV 
HCMV is an enveloped virus, which renders it very fragile and unable to 
persist in an external environment. As a consequence, transmission occurs by close 
contact with seropositive persons (sick or asymptomatic) excreting viral particles in 
oropharyngeal secretions, urine, semen, vaginal and cervical secretions, milk, saliva 
and tears (7, 119, 162, 231). Several modes of transmission have been described. 
HCMV transmission from mother to infant can occur at two different stages: 
during pregnancy in utero (congenital infection) or during or after delivery (perinatal / 
postnatal infection). Congenital CMV infection results from transplacental 
transmission of the virus during maternal viremia (8). Perinatal / postnatal HCMV 
infection from the mother to the child may occur through the genital tract during 
delivery or through breast milk, the later mode of transmission being the most spread 
in the world (73, 231, 275, 276). 
Children also acquire HCMV from other children or indirectly through 
environmental contamination (toys for instance). Group day care appears likely to 
result in early acquisition of HCMV. Pass et al. demonstrated that children in day care 
shed virus in saliva and urine, exposing virus to other children, nursery workers and 
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mothers (210, 211). The analysis of HCMV DNA isolated from infected children 
attending the same day care centre supports child to child transmission. Adler 
examined the HCMV DNA pattern following restriction endonuclease digestion of 16 
children from the same day care centre and he found out that two groups of children 
were excreting the identical viral strains (3). Hugo et al. showed that HCMV survives 
30 minutes on toys and the analysis of children’s oral behavior showed that every 2 to 
3 minutes they put toys and hands in their mouth (129), favoring HCMV 
environmental transmission. 
In adults, transmission mostly occurs through sexual activity because of the 
presence of the virus in genital tract. HCMV antibody prevalence in teenagers doubles 
during the first year of sexual activity (311). Seropositivity is related to the number of 
sexual partners and the age of onset of sexual activity (50, 214, 256, 270). 
Finally, the last mode of transmission in industrialized countries is the 
iatrogenic infection, which includes blood transfusion or organ transplantation from a 
seropositive donor. In 1983, Adler reported that i) seropositive blood donors are the 
source of HCMV infection for seronegative patients and that ii) the number of donors 
and the volume of blood transfused to recipients impact the incidence of HCMV 
infection (4). Gilbert et al. demonstrated that the leukocytes are the components 
responsible for infection; therefore filtration of blood through a leucocyte filter can 
prevent HCMV infection (97). 
3.2.3 Treatment of HCMV infection 
The treatments described in this section are usually given to 
immunocompromised patients such as transplant recipients and HIV patients, as in the 
immunocompetent patient, HCMV is usually not treated. 
There are currently three clinical strategies for the management and prevention 
of CMV disease in immunocompromised individuals: i) the prophylactic therapy, 
which consists in treating all patients irrespective of the risk of CMV disease before 
viral replication is detected, ii) the pre-emptive therapy, which is given to patients 
with a high risk of future disease where early viral replication is occurring and iii) 
treatment, which consists in treating patients showing evident clinical symptoms 
(223). 
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Table 1: Synopsis of the timing of the administration of the different strategies. Adapted from 
Griffiths et al, JAC, 2003 (109). 
 
To date, four antiviral agents have been licensed: ganciclovir (GCV), its 
prodrug valganciclovir (VGCV), foscarnet (257) and cidofovir (CDV). Intravenous 
GCV and oral VGCV are used as a first-line treatment and FOS and CDV are used as 
alternatives to the first two drugs. These two second line drugs have a potential for 
significant toxicity (renal or hematologic toxicity), therefore only patients with 
established CMV disease are treated. All four drugs target the viral DNA polymerase 
(47, 66, 269) and prolonged antiviral treatment has led to the development of HCMV 
cross-resistant strains (46, 116, 267, 282); therefore development of new drugs is 
needed. Some candidates have been studied with diverging outcomes. Maribavir had 
promising results with several Phase I and II trials which revealed good 
bioavailability and tolerability (18, 79, 296), however a recent Phase III trial showed 
some limitations (180) and the occurrence of a resistant strain was reported (279). The 
latest drug, in clinical development, Letermovir (known as AIC246), interacts with 
the UL56 subunit involved in viral DNA processing and packaging. As for now, no 
resistance has been reported (101, 167). 
3.3 General characteristics 
HCMV, alternatively known as Human Herpesvirus 5 (HHV-5), belongs to the 
Herpesviridae family, which contains 8 viruses known to cause disease in humans 
and which are classified in 3 subfamilies: alpha-, beta- and gammaherpesvirinae. 
HCMV belongs to the Betaherpesvirinae subfamily, which is characterized by a long 
replication cycle in cell culture and traditionally, a strict species specificity. HCMV 
has a divergent cell tropism, however, in human hosts, although HCMV infects nearly 
all differentiated cell types, including fibroblasts, hematopoietic, endothelial and 
epithelial cells (reviewed in (263)), a few cell types do not support productive 
infection counting lymphocytes and polymorphonuclear leukocytes (106, 264). 
Tropism is not determined by the expression of entry receptors on the cell surface, 
Term used When drug given Risk of disease Acceptable toxicity 
Treatment Once disease apparent Established High 
Pre-emptive therapy After systemic detection High Medium 
Prophylactic therapy Before active infection Low Low 
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rather, non-permissive cells allow viral binding and internalization but block viral 
replication at a post-penetration step (263, 265). 
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Table 2: Viruses from the Herpesviridae family causing disease in humans (213). a Values 
obtained in different laboratories. 
 
Type Synonym Subfamily Genome size (kbp) 
HHV-1 Herpes Simplex 1 α  152 
HHV-2 Herpes Simplex 2 α 155 
HHV-3 Varicella zoster virus α 125 
HHV-4 Epstein Barr virus γ 172 
HHV-5 HCMV β 235 
HHV-6A and 6B 
Roseolovirus, Herpes 
lymphotropic virus 
β 159-170a 
HHV-7  β 145 
HHV-8 
Kaposi's sarcoma-
associated herpesvirus 
γ 170-210a 
 
3.3.1 Virion structure 
HCMV virion structure is typical of other herpesviruses although it is larger 
and has a more irregular envelope (168, 192). HCMV genome is composed of a 
double stranded DNA molecule of ~235 kbp contained in an icosahedral capsid of 
125 nm enclosed in a proteinaceous layer called tegument (or matrix). The tegument 
is surrounded by a host cell derived lipid bilayer envelope carrying a large number of 
virus-encoded glycoproteins, and all together, the components generate viral particles 
ranging from 200 to 300 nm in diameter (130, 190). 
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Figure 2: Structure of a HCMV viral particle (Image reproduced from Human 
Cytomegalovirus, Human virus guides 3; Edited by Vincent C Emery, International Medical 
Press, 2007) 
3.3.1.1 The genome 
The HCMV genome is the largest of all herpesviruses. It is composed of two 
unique regions of DNA: a unique long sequence (UL) and a unique short sequence 
(US) flanked by internal and terminal repeated sequences. The orientation of UL and 
US, due to recombination between flanking inverted repeated sequences, promotes the 
production of 4 distinct isomers (261). In total the genomes encodes for 200-220 
genes, depending on the viral strains (clinical versus laboratory strains). This 
discrepancy is explained by the extensive passages in fibroblasts of the laboratory 
strains, which led to a large deletion (the sequence comprised between UL128 and 
UL131) and the accumulation of punctual deletions and mutations in laboratory 
strains (32, 71, 198). 
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3.3.1.2 The nucleocapsid 
The nucleocapsid is organized on a T=16 icosahedral lattice which is 
composed of 150 hexons (capsid faces) and 12 pentons (capsid vertices). The HCMV 
nucleocapsid is composed of 4 structural proteins (192): 
- The major capsid protein (MCP), encoded by the gene UL86, is the 
main component of the nucleocapsid (36) and forms the hexons and 
pentons of the icosahedral capsid, 
- The minor capsid protein (mCP), encoded by the gene UL85, forms the 
trimers (together with the minor capsid binding protein) that connect 
hexons and pentons together, 
- The minor capsid protein-binding protein (mC-BP), encoded by the 
gene UL46, interacts with mCP (96) and forms trimers, 
- The smallest capsid protein (SCP), encoded by a sequence between the 
genes UL48 and UL49 (referred to as UL48/49), decorates the outside 
of the nucleocapsid and binds MCP on the tip of hexon subunits (158, 
323). SCP is also essential for HCMV infection in vivo (20). 
Besides these structural proteins, nucleocapsid contains several internal, 
closely related proteins, which catalyse the assembly process: the assembly protein 
(AP) and proteinase precursors (also known as assemblin) both encoded by different 
regions of the gene UL80. The AP precursor (pAP), which supplies the nuclear 
localization signal (NLS), interacts with MCP in the cytoplasm, with enables the 
complex MCP/pAP to translocate to the nucleus (220, 317). The assemblin, which 
have counterparts among all herpesviruses, is important for assembly and maturation 
of the nucleocapsid and is essential for the production of infectious viral particles (72, 
95, 310). 
3.3.1.3 The tegument 
Approximately 20 to 25 known virion-associated tegument proteins have been 
identified; most of these proteins are phosphorylated (192) and highly immunogenic 
(24). Amongst them, the most abundant tegument proteins are pp65 (encoded by the 
gene UL83), pp150 (encoded by the gene UL32) and pp71 (coded by the gene UL82), 
which represent 15%, 9% and 9% of the virion mass, respectively (302). The 
tegument protein pp65 contains two NLS, which allow it to translocate to the nucleus 
minutes after infection (91). The expression of pp65 occurs early during infection. 
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Once expressed, pp65 accumulates in the nucleus and finally translocates to the 
cytoplasm at late times post-infection to be incorporated in the virions (121). One 
function of pp65 is its capacity of both autophosphorylation and phosphorylation of 
immediate early (IE) viral proteins by its serine/threonine kinase activity, preventing 
the cleavage of IE and subsequent presentation through the major histocompatibility 
complex class 1 molecules (MHC-I) (98). The transactivator tegument protein pp71 
activates the IE gene expression (273) and is necessary for efficient viral replication 
(reviewed in (141)). pp150 plays a role in the assembly and egress of virus particles 
since it is necessary to incorporate nucleocapsids into virus particles (302). 
Besides proteins, the tegument contains as well cellular and viral RNAs that 
are incorporated non-specifically during virion assembly (22, 107). 
3.3.1.4 The envelope 
HCMV particles have a lipid bilayer envelope derived from the endoplasmic 
reticulum (ER) or ER Golgi intermediate complex (ERGIC) (126). The envelope 
contains three major glycoprotein complexes: 
- The glycoprotein B (gB), encoded by the gene gpUL55. gB is 
expressed as a disulphide-linked homodimer and the resulting complex 
is named glycoprotein complex I (gcI). This complex has several 
functions including: i) binding to heparin sulphate proteoglycans 
(HSPG) and receptors expressed on the cell surface of target cells (21, 
53, 81, 190, 307), and ii) cell-to-cell spread infection (203); although a 
recent study suggests that the main role of gB is to induce fusion rather 
than binding receptors (315). gB is a major target of neutralizing 
antibodies, making it the favourite candidate for the elaboration of 
vaccines (191, 192, 274). 
- The disulphide-linked dimer gM:gN (also referred to as gcII), the most 
abundant protein component of the envelope, is encoded by gpUL100 
and gpUL73, respectively. This complex has also several functions 
including: i) binding to HSPG on the target cells (142), ii) implication 
in assembly and replication (gM) (154), and iii) protection of the virus 
from neutralizing antibodies (gN) (153). 
- The heterodimer complex gH:gL (also referred to as gcIII) encoded by 
gpUL75 and gpUL115, respectively, is important for fusion (51, 52, 
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153). gH:gL can interact with two distinct component, gO or the 
complex UL128-131 which is responsible for HCMV tropism. In 
endotheliotropic HCMV strains, gH:gL interacts with UL128-131, 
allowing viral particles to enter and replicate into epithelial and 
endothelial cells (amongst others) (2, 93, 115, 238, 239, 305). In 
contrast, fibrotropic HCMV strains acquired mutations in the UL128-
131 genes and cannot assemble gH/gL/UL128-131 and, therefore, 
cannot infect endothelial and epithelial cells, leukocytes, and 
monocytes (32, 71, 115). gO is important for HCMV entry into 
fibroblasts (300) and is involved in the incorporation of the complex 
gH :gL in viral particles and the virus release (137, 237, 314). 
3.3.2 HCMV replication cycle 
As for other herpesviruses, genes are transcribed by the cellular RNA 
polymerase II and gene expression occurs via a temporal cascade which counts an 
immediate-early (IE), an early (E) and a late (L) phase. The expression of IE proteins 
follows virus entry and does not require the expression of any other viral proteins. IE1 
and IE2 encoded by the genes UL123 and UL122, respectively, are the main IE 
proteins and are essential for the regulation of the expression of E and L proteins.  
The expression of E proteins occurs 4-12 hours post-infection. During this E 
phase, non-structural proteins important for viral replication, packaging and 
maturation of viral particles are produced. These E proteins include amongst others: 
the viral DNA polymerase (encoded by UL54), a viral DNA polymerase processivity 
factor (encoded by UL44) and the protein kinase (encoded by UL97), the latter 
controls the phosphorylation of the antiviral drug GCV (172, 283).  
Finally, during the L phase, the viral genome is replicated and viral structural 
proteins are expressed. The essential functions of these L proteins are nucleocapsid 
maturation, DNA encapsidation, virion maturation and egress of viral particles from 
the cell. 
3.4 HCMV tropism and virus entry 
Herein, I will define “entry” as all the processes from the initial binding of 
viral particles to the initiation of replication with the expression of IE proteins. 
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3.4.1 HCMV factors associated with viral tropism 
Tropism differs between clinical and laboratory strains. As written in chapter 
3.3.1.4, the difference observed in the tropism is based on the loss during several 
passages on fibroblasts of the loci UL128, UL130 and UL131A in laboratory strains 
(135), which are major viral determinants of HCMV tropism. The presence of the 
complex UL128-131 on the viral envelope of endotheliotropic strains, and its 
association with the complex gH:gL (gH:gL:UL128-131) allows HCMV to enter 
epithelial and endothelial cells (115, 236). Wang and Shenk demonstrated that an 
intact UL128-131 locus in AD169 (after repairment of the gene UL131) is important 
for infection of both epithelial and endothelial cells (304), and Ryckman showed that 
the complex gH:gL:UL128-131 plays an important role in endocytosis and pH-
dependent entry into these cells (238). In contrast, in fibrotropic strains, the absence 
of this complex and the presence of another complex (gH:gL:gO) allows HCMV entry 
into fibroblasts (300). It has been recently demonstrated that the cell type in which 
viral strains are produced plays a major role in the determination of the tropism of 
progenies. When an endotheliotropic strain is grown in fibroblasts, progenies infect 
both fibroblasts and endothelial cells in a cell-free virus manner, whereas when the 
same strain is grown in endothelial cells, progenies infect only fibroblasts in a cell-to-
cell manner. This difference was explained by the amount of UL128-131 incorporated 
in virions where fibroblasts-derived progenies displayed higher amounts of this 
complex compared to endothelial cells-derived progenies (253). 
3.4.2 HCMV entry mechanisms 
In human hosts, HCMV infects nearly all cell types, including fibroblasts, 
hematopoietic, endothelial and epithelial cells (reviewed in (263)). This extensive host 
cell range correlates with the potential for clinical manifestation of HCMV disease in 
almost every organ. This broad cellular tropism suggests that, to enter human cells, 
HCMV might use receptor(s) common to most cells (52). The entry of HCMV into 
human cells is a complex process requiring sequential interaction between multiple 
cellular and viral components.  
On many HCMV-permissive cell types, HCMV glycoproteins including gB 
homodimers and gM:gN heterodimers, first transiently attach to HSPG (i.e. the 
tethering step) (55) before stable attachment to and entry through transmembrane 
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protein receptors (51). HCMV enters cells via two distinct mechanisms depending on 
the cell type. In human fibroblasts it occurs by a pH-insensitive membrane fusion (54) 
whereas in human epithelial and endothelial cells, the virus enters via endocytosis in a 
pH-dependent manner (19, 238). Both fusion and endocytosis display common steps 
in HCMV entry involving cellular receptors. Numerous cellular receptors have been 
described, although, none appears to be required in all cell types. These receptors 
include epidermal growth factor receptor (EGFR) (34, 131, 308), platelet-derived 
growth factor receptor alpha (PDGFRα) (272, 301) and various integrin family 
heterodimers: α2β1, α6β1, αvβ3 integrin (81, 305). 
The cellular cytoskeleton plays an important role for entry and nuclear 
translocation of many viruses. It is composed of three different components, namely 
microtubules, actin microfilaments and intermediate filaments (IF). Entry and 
trafficking of herpesviruses was shown to be dependent on both the actin and the 
microtubule cytoskeleton, which cooperate in order to deliver the viral genome to the 
nucleus on infected cells (173). In the case of HCMV, internalization of the viral 
particle requires an intact actin cytoskeleton (19). Following viral internalization and 
release of the nucleocapsids into the cytoplasm, the nucleocapsids associate with the 
microtubule cytoskeleton and are transported towards the microtubule-organizing 
centre (MTOC) located near the nucleus (207). However, one must be cautious in the 
interpretation of such results since inhibitors of microtubules and microfilament affect 
IF organization (224). Currently little is known about the involvement of IF in virus 
entry, however, in 2009, Miller et al. reported that an intact vimentin cytoskeleton, an 
IF protein, is required for HCMV entry into fibroblasts (186). 
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Figure 3: Cartoon illustrating the entry steps of HCMV in human cells (illustration created 
thanks to Servier Medical Art, http://smart.servier.fr/servier-medical-art). 
 
3.5 HCMV cross-species infection 
Cytomegaloviruses are found in many mammalian species and have coevolved 
with their respective hosts, which has led to the traditional paradigm that CMVs are 
generally considered to be highly species-specific since their first isolation in cell 
culture in 1955. Several groups demonstrated that replication of CMVs can occur in 
cells of their own or a closely related species. In 1988, Lafemina et al. demonstrated 
that CMVs (simian CMV, mouse CMV and HCMV) enter cells from the other species 
and start replicating, which was observed by the production of IE proteins (156). 
Later, in 1992, Perot et al. demonstrated that chimpanzee cells are permissive to 
HCMV (216). Similar results were observed for mouse CMV (MCMV) and rat CMV 
(RCMV) (25, 266) where it was shown that MCMV replicates in rat cells but rat 
CMV fails to replicate in murine fibroblasts. 
Although cells of more distant species are usually non-permissive, it has also 
been reported that CMVs can enter these cells and express a subset of viral genes, 
which is followed by either a reduced release of infectious viral particles when 
compared to human fibroblasts (216), or an abortive infection (83, 146, 156). These 
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findings suggest that the restriction of CMV replication in non-permissive cells is due 
to a post-penetration block rather than a failure to enter cells. More recently, the 
molecular mechanism underlying CMVs specificity was investigated and several 
mechanisms have been described. Jurak et al. have demonstrated that MCMV 
infection of human cells induces apoptosis, and that inhibition of apoptosis enables as 
well rat cytomegalovirus to cross the species barrier and replicate into human cells, 
indicating that this mechanism is not specific to one type of CMV (140). More 
recently, the group of Tang assessed the involvement of the nuclear structure called 
ND10 (nuclear domain 10), also referred to as promyelocytic leukaemia nuclear 
bodies (PML bodies), in limiting cross-species infection. Several herpesviruses, 
including CMVs are capable of disrupting this domain (6, 132), whose components 
have been shown to have negative impacts on herpesviruses (125, 225, 240, 290), and 
various viral proteins have been identified as being related to ND10 and ND10 
proteins (reviewed in (241)). They demonstrated that during a cross-species infection, 
ND10 are dispersed by CMVs and that ND10 components are involved in blocking 
viral gene expression in such infections (57). 
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Introduction, part 2: 
 
Xenotransplantation 
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3.6 History of transplantation 
3.6.1 Allotransplantation 
Allotransplantation consists in transferring cells, tissues or organs between two 
genetically non-identical individuals of the same species. Over the past decades, 
allotransplantation has evolved from a “clinical experiment” to a very successful, 
often life-saving therapy and has emerged as the best therapy to treat patients with 
end-stage organ failure.  
The first notions of tissue transplantation were already described several 
millennia ago in ancient literature. For instance, the Sushruta Samhita, a Sanskrit text 
about surgery, described how Sushruta, one of the earliest surgeons known in history, 
practiced, in 600 BC, nasal reconstruction. In ancient times, nasal amputation was a 
common punishment for criminals and Sushruta would reconstitute patient’s nose 
with their own skin grafts cut from their cheek. According to their hagiography, in the 
3rd century AD, two Saints, St. Cosmas and St. Damian performed a leg 
transplantation to replace a cancerous leg with a leg from a dead black man (56). By 
the early 20th century, the French surgeon Alexis Carrel, pioneer of the vascular 
suturing technique and creator of the “perfusion pump” (a device allowing living 
organs to exist outside of the body during surgery) successfully reimplanted a kidney 
in the neck of the same dog. A few years later he reiterated the surgery between dogs 
and by his observations he concluded that the host response to the foreign graft (i.e. 
the immune system) was responsible for the allograft rejection (29-31). He was 
awarded in 1912 with the Nobel Prize in Physiology or Medicine for his work on 
vascular suture and the transplantation of blood vessels and organs. After the World 
War I, several kidney transplantations were performed but all of them failed due to 
rejection. Starting from 1950s, successful kidney transplantations were documented. 
The surgical team represented by Dr. Joseph Murray and Dr. John Merrill 
successfully transplanted on two occasions a kidney between two identical twins. First 
in 1954 between twin brothers whose recipient survived 8 years with a fully 
functional kidney (183); and second in 1956 between twin sisters whose recipient 
survived 55 years making her the longest surviving transplant recipient (199). It was 
becoming evident that the suppression of the recipient’s immune system was the key 
to allograft rejection. In the late 1950’s, one approach to suppress the recipient’s 
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immune system was to irradiate it. Patients were treated with sub-lethal radiations; 
however most of the patients’ cause of death was linked to the effects of radiation 
rather than rejection. The discovery and development of immunosuppressive agents 
10 years later opened an alternative possible pathway. In the 1960’s, Dr. Thomas 
Starzl demonstrated that a “cocktail” of immunosuppressive drugs was able to reverse 
allograft rejection and induce host tolerance towards the graft (278). This discovery 
opened the door to the transplantation of organs other than kidneys such as lungs, 
pancreas, heart and liver. 
The success of allotransplantation has led to a shortage in the supply of organs 
required to meet the increasing demand. In 2012, 1165 persons were in need of a 
transplant in Switzerland and nearly 10% died awaiting for an organ 
(Swisstransplant). The solution to this shortage is to find another kind of donor whose 
transplantation would be compatible with human. Xenotransplantation, defined as the 
transplantation of living cells, tissues or organs from one species to another, might be 
one possibility. Nowadays it has become a focus of interest and a very important area 
of transplantation research. 
3.6.2 Xenotransplantation 
The idea of a part man – part animal chimera has always fascinated men since 
several millennia. In mythology, gods of the Ancient Egypt were often represented 
with the body of a man and the head of an animal. Ra, god of Sun had the head of a 
falcon; Anubis, god of mummification and afterlife had the head of a jackal and 
Sobek, god of the Nile was seen as a crocodile-headed man. In Ancient Greece, 
several mythical monsters were also part human – part animal. Amongst others, 
centaurs were horses with the trunk and the head of a man, the Minotaur was a man 
with the head of a bull and the harpies were birds with the head of a woman. Cross-
species transplantation (or xenotransplantation) recipients can be considered as 
today’s chimera. The first xenotransplantation attempts were made without any 
knowledge of the species barrier, resulting in major failures. At first, cells and tissues 
comprised the majority of the transplants and later, with the mastering of the 
technique of vascularization of the graft and the development of immunosuppression, 
xenotransplantation of organs followed.  
In 1501, Mohammad Baha’ al-Dawla, an Iranian surgeon, performed the first 
bone tissue xenotransplantation by transplanting a patient suffering from an 
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osteomyelitis of the skull with a piece of a dog’s bone. In 1667, the first successful 
xenotransfusion was documented; a man suffering from severe fever was cured after 
being transfused with blood from a lamb (80). In the end of the 19th century, testicle 
xenotransplantation from ape to human was used as a “human revitalization 
transplantation” (64). In 1889, Charles-Edouard Brown-Séquard was a physician 
suffering from week physical strength subsequent to his advanced age who injected 
himself with an extract of crushed testicles from guinea pig and dog, which resulted in 
an improved physical state (252). However, in 2002, Cussons et al. demonstrate that 
regarding the output of the testicle preparation injected, Brown-Sequard was victim of 
the placebo effect (61). Later, in 1920, Voronoff executed several chimpanzee-to-
human sexual organ xenotransplantations. He performed several testis transplantations 
believing that the hormones produced by the xenograft would rejuvenate his patients. 
He also transplanted ovaries of female apes to women in order to treat menopause 
(13). More surprisingly, he transplanted a woman’s ovary into a female chimpanzee 
that he then inseminated with human sperm and the outcome was unsuccessful (33). 
At the beginning of the 20th century, the first organ xenotransplantation began 
with the mastering of the suturing technique, i.e. the anastomosis. In 1906, Mathieu 
Jaboulay realised the first true-reported xenotransplantation where he transplanted two 
patients with kidneys from pig or goat; however both attempts failed due to 
thrombosis (134). During that time, several animal-to-human kidney transplantations 
were unsuccessfully attempted; all these failures were directly linked to the absence of 
immunosuppression. In 1964, Reemtsma performed the most successful chimpanzee-
to-human kidney transplantation with the graft surviving 9 month (229). With the 
numerous failures, the discovery of immunosuppressive drugs and the acceptance of 
deceased organ donors as a new source of allogeneic organs, the enthusiasm for 
xenotransplantation vanished and focus went back to allotransplantation. The new 
xenotransplantation era began in 1984 with the most famous baboon-to-human heart 
transplantation to a 12-day-old female baby known as “Baby Fae” who died 20 days 
after surgery (128, 155). Most of the hopes put in xenotransplantation died with Baby 
Fae and it was only in 1992 that attempts resumed (277).  
Currently, clinical pig-to-human trials involving porcine islet cells are 
performed in New Zealand. Six patients with type I diabetes were transplanted with 
encapsulated neonatal porcine islet cells secreting insulin. Preliminary results showed 
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that after transplantation, patients’ insulin dose was significantly reduced. One of the 
patients is said to be insulin-free (Living cell technologies, 
http://www.lctglobal.com/Products-and-Services/Diabecell/). These findings need to 
be confirmed and published; however, this recent success demonstrates the great 
potential of xenotransplantation. For a long period of time, primates were considered 
the best organ donors for xenotransplantation due to their relatively similar immune 
system. However, being closely related to human, they represent a higher risk for the 
transmission of infectious diseases compared to other more distant species. Miniature 
pigs represent the more suitable source of organ for several reasons. They can be 
housed in a pathogen-free environment, they are easy to breed and have a bigger 
number of offspring and their organs share some similarities with human organs 
regarding size and physiology. Finally, scientists have now a considerable genetic 
engineering knowledge, which allowed them to create pigs expressing several human 
complement regulatory proteins (181) responsible for the delay of xenograft rejection. 
This approach also presents some unknowns and the most profound obstacle to 
xenotransplantation remains the immunological rejection of the organ. The potential 
risk of cross-species infection associated with the use of porcine tissues in humans 
requires considerable attention. Indeed, xenotransplantation creates a unique situation 
in which tissues from two species will be in an intimate contact for a long period of 
time raising the question of possible transfer of pathogens between the graft and the 
recipient. Most of the research has been focused on donor-derived infections, 
neglecting host-derived infection with potentially direct consequences for the graft. 
3.7 Limits of xenotransplantation 
Before xenotransplantation can be regarded as a veritable clinical alternative to 
allotransplantation, several limitations need to be overcome. Limitations can be 
classified into two categories: i) biological issues including the immunological and the 
infectious aspects, and ii) the non-biological issues counting ethical, religious and 
legal facets. In the following chapter I will discuss the biological issues with a focus 
on the possible transfer of pathogens between the porcine graft and the recipient. 
3.7.1 Classification of xenografts 
Xenografts can be classified into two groups regarding the nature of the 
xenograft and the speed of rejection, including vascularized xenografts (i.e. solid 
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organs) and non-vascularized xenotransplants (also referred to as free tissue graft) 
including among them pancreatic islets, bone marrow and neuronal cells. The main 
difference between the two groups is the time spent between surgery and exposure of 
the graft to the recipient’s blood. Vascularized organs are immediately in contact with 
the recipient’s circulation after transplantation, whereas a free tissue graft will not be 
exposed until revascularization has occurred, resulting in a faster/immediate rejection 
for the former. Rejection of vascularized xenografts occurs mainly by humoral 
mechanisms whereas free tissue xenotransplants are rejected mainly by cellular 
mechanisms. 
In 1970, Sir Roy Calne was the first to described two types of vascularized 
xenotransplants depending on the relation between the recipient and the donor: 
concordant and discordant (26). The former consists in transferring organs between 
two phylogenetically closely related species, for instance nonhuman primate-to-
human, whereas the latter describes combination of phylogenetically distant species 
such as pig-to-human transplantation. A discordant xenotransplantation is 
characterized by a fulminant rejection occurring within minutes to hours after 
transplantation whereas a concordant xenotransplantation results in rejection more 
than one day after surgery.  
The different rejection mechanisms described in the following chapter, except 
for IBMIR, are involved in the rejection of vascularized xenografts. 
3.7.2 The immunologic barrier 
Following allotransplantation, one hurdle of considerable importance that the 
graft will encounter in the recipient is the immunological barrier, and in the case of 
xenotransplantation, the immune response towards the graft, which depends on the 
phylogenetic distance, will be stronger. Indeed, the more distant the two species are, 
the stronger the recipient’s response will be, which is a big concern regarding pig-to-
human transplantation. The humoral and cellular immune systems are involved at 
different stages of the xenograft rejection and are named: hyperacute rejection (HAR) 
(147), acute humoral xenograft rejection (AHXR) (222) (also referred to as acute 
vascular rejection, AVR, or delayed xenograft rejection, DXR), acute cellular 
xenograft rejection (ACXR) (150) and chronic rejection (257), which are discussed 
below. 
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3.7.2.1 Hyperacute rejection (HAR) 
HAR characteristics include diffuse interstitial haemorrhage, oedema and 
thrombosis in capillaries and small vessels (12), leading to the destruction of the 
xenograft within minutes to hours after surgery. HAR occurs only in vascularized 
discordant xenotransplantation due to the presence of preformed xenoreactive natural 
antibodies (XNA) in the discordant recipient responsible for this violent rejection. 
These antibodies, discovered in 1984 by Galili, are directed against the glycosidic 
carbohydrate epitope Gal (88). Gal is a terminal disaccharide linked to N-
acetyllactosamine on glycoproteins and glycolipids by the enzyme α(l,3)-
galactosyltransferase (αGal). This enzyme is expressed in New World monkeys and 
non-primate mammals such as pigs but is absent in high primates where the gene 
sequence suggests an inactivation of the enzyme (90); therefore humans and Old 
World monkey do not express the Gal antigen (89). Anti-Gal antibodies binding to the 
porcine endothelium, complement deposition, platelet activation and aggregation and 
coagulation are responsible for the disruption of vascular pEC. Several strategies 
aiming at either the recipient or the donor have been developed to prevent HAR. One 
approach consists in depleting the recipient of XNA, which includes: plasmapheresis 
(which also perturbs the coagulation and the complement cascade components since 
they are discarded along with the antibody fraction), immunoadsorption (289), 
perfusion of a porcine “sponge organ” such as a liver or a kidney (14) or 
administration of decoy carbohydrate polymers (319). However, these techniques only 
reduce temporally the levels of XNA and titres of these antibodies recur quickly. 
Other strategies based on genetic engineering of the donor were established: i) the 
development of transgenic pigs expressing human complement regulatory proteins 
capable of inhibiting the antibody-mediated activation of the classical complement 
cascade (40, 69, 181) and ii) the generation in 2002 of αGal knocked-out (αGalKO) 
pigs by the disruption of the enzyme gene (218).  
3.7.2.2 Acute humoral xenograft rejection 
AHXR occurs in concordant or in discordant models when HAR is prevented 
and is for now the main hurdle in xenotransplantation. This second rejection event is 
characterized by vasculitis, thrombosis, oedema and haemorrhage leading to the 
xenograft failure in 2 to 5 days. As for HAR, antibodies directed against αGal play a 
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major role in AHXR; however, xenografts originating from αGalKO pigs and thus not 
expressing αGal are still susceptible to AHXR, suggesting that non-Gal antibodies are 
also involved in this delayed rejection (102). This humoral response will cause 
rejection by fixation and activation of the complement and activation of the 
endothelium that will in turn induce vascular integrity loss, secretion of cytokines, up-
regulation of adhesion molecules on endothelial cells and activate the coagulation 
pathway (221). 
The factors triggering AHXR are currently not well defined and as a 
consequence treatments to control AHXR are still under investigation. Some 
treatments include transgenic donors deleted for pro-coagulant genes or 
overexpressing anti-coagulant factors (60). 
3.7.2.3 Acute cellular xenograft rejection 
Challenges in avoiding HAR and AHXR have made the characterization of 
ACXR in discordant xenotransplantation challenging. ACXR generally accompanies 
AHXR and is characterized by infiltration in the solid organ xenograft of T cells, B 
cells, natural killer cells (NK cells), neutrophils and macrophages. The prevention of 
ACXR is based on the induction of T cell tolerance including co-stimulation blockade 
(27, 123), donor specific transfusion (infusion of donor cells in the recipient) (41, 
104) and the induction of mixed haematopoietic chimerism by haematopoietic cell 
transplantation (the recipient has hematopoietic cells from both his own and the donor 
origin) (38, 161).  
3.7.2.4 Chronic rejection 
The changes in the graft associated with a hampered function are called 
chronic rejection. In xenotransplantation, it is speculated that xenografts surviving all 
the previous rejection events will develop chronic rejection. For instance, in a 
concordant aortic hamster-to-rat transplantation model, an accelerated arteriosclerosis 
occurred (thickening and loss of the elasticity of arteries are considered as a sign of 
chronic rejection) (247). For now, in order to further investigate chronic rejection in a 
context of discordant xenotransplantation, HAR, AHXR and ACXR still need to be 
overcome. 
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3.7.2.5 Instant blood mediated inflammatory reaction (IBMIR) 
This rejection event only occurs after free tissue xenotransplantation. Cellular 
xenografts are revascularized in and by the recipient, therefore grafts escapes HAR 
and AHXR (151). Once in the recipient’s blood circulation, a high amount of cells is 
lost due to IBMIR that is characterized by a rapid activation of the coagulation and 
complement system, infiltration of leukocytes and binding and activation of platelets. 
All these events will in the end lead to the formation of a thrombus. In 2006, Dwyer et 
al. demonstrated that mice pancreatic islet cells expressing human CD39 (an 
ectonucleotidase that degrades the platelet agonist adenosine triphosphate) delayed 
IBMIR when incubated with human blood (74). In 2012, Wheeler et al. generated a 
transgenic swine expressing human CD39, however the protective capacity of these 
cells against IBMIR still needs to be investigated. 
3.7.2.6 Coagulation 
Coagulation is a tightly regulated process triggered by damages to blood 
vessel walls and exposure of tissue factor to circulation, triggering the production of 
thrombin (176). During xenotransplantation, the balance between coagulant and anti-
coagulant factors is lost, resulting in thrombosis in the xenograft (59). There are two 
major incompatibilities between porcine anti-coagulant factor and human coagulant 
factors: 
- between human protein C and porcine thrombomoduline which results 
in an inefficient conversion by the latter of human thrombin from a 
pro- to an anti-coagulant form, initiating clotting (148, 233), 
- between human factor X (FX) and porcine tissue factor pathway 
inhibitor (TFPI), resulting in an incapacity of TFPI to inhibit FX (149), 
although this incompatibility is controversial (164), 
- between porcine von Willebrand Factor (vWF) and human platelets 
where porcine vWF high affinity for human platelet results in a 
spontaneous aggregation of platelets (251). 
There are no pharmacological therapies for the moment because long-term 
treatment of the recipient is both dangerous and unpractical. The current strategies are 
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to generate αGalKO transgenic pigs expressing anti-coagulant or anti-thrombotic 
factors. 
3.7.3 The non-immunologic barrier: the risk of zoonosis 
Zoonosis refers to the transmission of pathogens from animals (whether wild 
or domesticated) to humans. Such zoonotic catastrophes previously occurred in 
history with distressing reports, including: HIV pandemic, Creutzfeldt-Jakob disease, 
Ebola virus outbreaks, and, more recently, the severe acute respiratory syndrome 
scare. The potential transmission of pathogens between pig and human is one 
important concern in xenotransplantation (referred to as xenozoonosis). Although the 
risk is considered to be smaller with pig organs than with organs from primates, 
transmission might still occur as a consequence of intensive immunosuppression, and 
if the pathogen is then transmitted from the recipients to human population, as regards 
to some of the diseases listed above, it can quickly become a public health issue (309). 
In this chapter, I will first discuss about pathogens (focus on viruses) that have 
been shown to be transmitted from pigs to humans and describe how this transmission 
risks can be prevented. In the second part I will focus on the infections of the graft by 
recipient pathogens; this issue has been taken into consideration only recently and is 
more difficult to prevent. 
3.7.3.1 Donor to recipient transmission 
It is generally believed that pigs can easily be raised free of infectious agents 
in a specific pathogen-free (SPF) environment, however it has been shown that 
transplacental infection of foetuses can occur with a number of viruses, thus 
periodically, infection of pigs occurs. In this chapter, I will discuss about selected 
exogenous and endogenous viruses and the potential xenozoonoses risk they present. 
Because of the lack of specific microbiologic assays to detect pathogen responsible 
for yet unknown diseases (i.e. linked to unknown clinical syndromes or not related 
with any identified disease), this section contains an incomplete list. With time and 
the development of new detection techniques, this list might certainly extend. 
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3.7.3.1.1 Porcine Influenza virus (Orthomyxoviridae, Influenzavirus 
A) 
Several cases of human infection with porcine flu have been detected where 
swine influenza virus was isolated from humans (124, 312, 313). Because of several 
outbreaks, porcine flu is considered a major public health risk. These epidemics 
include: the Spanish flu (also referred to as the 1918 flu pandemic) causing 50 to 100 
million of death that was suspected to be caused by swine influenza virus and more 
recently the swine influenza outbreak that first manifested in Veracruz (Mexico) and 
killed an estimated 284,500 people worldwide (65). Swine are very susceptible to 
human and avian influenza but the infection is usually subclinical or results in a minor 
disease. In contrast, swine influenza infection in pigs develops rapidly with high fever 
by 24-36 hours post-infection that lasts 24-48 hours and hyperpnea/dyspnea due to 
interstitial pneumonia. By 96-120 hours post-infection, fever and clinical signs of 
respiratory distress diminish. Swine influenza virus is highly contagious and very few 
herds are free of infection. However, elimination of infection is possible by isolating 
early weaning from sows and strict biosecurity measures. 
3.7.3.1.2 Nipah virus (Paramyxoviridae, Henipavirus) 
An outbreak where pigs were suspected to be the intermediate hosts occurred 
in 1999 in Malaysia among pig farmers causing acute respiratory syndrome and fatal 
encephalitis in humans (166). Another Nipah virus infection was documented in 
Singapore in humans working in an abattoir with pigs imported from Malaysia (43). 
Transmission is thought to occur via respiratory droplets, contact with throat or nasal 
secretions from the pigs (184) and one can think that contact with tissues of a sick 
animal could lead to infection. Human-to-human transmission was recorded (114, 
244) resulting in high mortality rates, which makes it a serious public health issue. 
The absence of treatments and the high contagiousness of Nipah virus in pigs make 
the eradication of herds the best method to control the infection. 
3.7.3.1.3 Menangle virus (Paramyxoviridae, Rubulavirus) 
Menangle virus was first isolated in Australia in 1997 (35). Reports have 
demonstrated that two pig framers, later tested positive for Menangle virus antibodies, 
developed severe influenza-like illness including fever, chills, severe headache, 
myalgia and a macular rash (35), but both farmers subsequently recovered. To date, 
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the route of transmission from pigs to humans is still unknown. Adult pigs and new-
born do not show any symptoms, but one characteristic of the diseases is a decline in 
rate and number of live piglets per litter and a large number of mummified foetuses 
and stillborn. For stillborn, severe degeneration of the brain and spinal cord and grave 
skeletal/craniofacial defects including arthrogryposis (joint contracture), 
brachygnathia (abnormal shortness of the lower jaw) and kyphosis (also referred to as 
roundback) have been observed (171). This virus can be eradicated by disinfection 
and temporary depopulation of individual units in the pig farm, which was used to 
control the 1997 outbreak. 
3.7.3.1.4 Porcine circovirus (Circoviridae, Circovirus) 
Porcine circovirus (PCV) is one of the major pathogens of swine. Infection of 
humans by PCV is controversial. Some groups did not detect any antibodies in the 
general population (9, 10) or in veterinarians working with infected pigs (78), whereas 
Tischer et al. found antibodies to PCV in patients suffering from fever of unknown 
ethiology (294); however an in vitro study demonstrated that infection of human cells 
by PCV results in a non-productive infection (117). In pigs, the infection named 
porcine circoviral disease (PCVD) or porcine circovirus associated disease (PCVAD) 
(previously referred to as post weaning multisystemic wasting syndrome (PMWS)) is 
characterized by progressive dyspnea and an extreme weight loss in piglets. PCV-free 
pigs can be obtained by isolating PCV-free pigs from PCV-immune sows (protected 
as a result of passive acquisition of antibodies) during the first 4 weeks of life and 
breeding them in a PCV-free environment. 
3.7.3.1.5 Encephalomyocarditis virus (EMCV) (Picornaviridae, 
Cardiovirus) 
Although antibodies for EMCV have been demonstrated in human populations 
(293), there is no report that this virus causes human heart disease. However, Brewer 
et al. demonstrated that EMCV infects human myocardial cells in vitro (23). EMCV is 
responsible for high mortality in young pigs and reproductive failures in pregnant 
sows. Piglets suffer from myocarditis and encephalitis and myocardial failure often 
results in sudden death. An inactivated vaccine for EMCV infection in swine is 
commercially available and has been shown to be effective. It is also important to 
minimize the interaction between rodents and swine (rodents are naturally infected 
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with EMCV and are believed to be the principal reservoir of the virus (1)) and to 
prevent contact with pigs either directly or indirectly via contaminated food or water. 
3.7.3.1.6 Porcine coronavirus (Coronaviridae) 
In Japan, 5% of human milk samples collected from mothers were tested 
positive for the presence of antibody against porcine transmissible gastroenteritis 
coronavirus (TGEV) (292). Four coronaviruses have been detected in pigs, including 
TGEV, porcine respiratory coronavirus, porcine epidemic diarrhea virus and 
hemagglutinating encephalomyelitis virus. From all these four circoviruses, TGEV is 
the most common and the most studied (242) and is the only coronavirus that has been 
suggested to be transmitted to humans (292). Swine infected with TGEV have 
reduced capability for digesting food and die from dehydration. Preventive measures 
for negative herds include maintaining a closed herd and implementing strict 
biosecurity practices. 
3.7.3.1.7 Herpesvirus (Herpesviridae) 
In this paragraph, three porcine herpesviruses will be discussed: pseudorabies 
virus, porcine lymphotropic herpesvirus and porcine cytomegalovirus. Although to 
date no transmission from pig to human has been reported, these viruses cause 
persistent infections and could represent a xenozoonotic risk. 
 
Ø Pseudorabies (PRV) (α-herpesvirus, Varicellovirus) 
Reports of human infection are limited and are based on seroconversion rather 
than virus isolation. In pigs PRV infection is usually asymptomatic but it can cause 
severe respiratory disease, neurological disease, and abortions. Piglets are more 
susceptible and suffer from severe respiratory disease with high mortality. In 2004, 
Hayashi et al. demonstrated that the anti-Gal antibodies in human serum are important 
for neutralizing PRV from pigs expressing Gal (118). The remaining question would 
then be whether humans would be able to neutralize PRV from Gal-KO pigs? 
Although the ability of PRV to cause latent infection complicates its eradication and 
control, it is possible to prevent exposure of a negative herd to PRV through strict 
quarantine and isolation procedures. 
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Ø Porcine lymphotropic herpesvirus (PLHV) (γ-herpesvirus, 
Rhadinovirus) 
To date, three PLHV have been discovered: PLHV-1 and PLHV-2 in 1999 
(77) and PLHV-3 (more distant genetically from PHLV-1 and PLHV-2) in 2003 (44). 
In pigs immunosuppressed and subjected to allogeneic hematopoietic stem cell 
transplantation, PLHV-1 is associated with a porcine lymphoproliferative disease of 
high mortality (103, 127) which resembles the post-transplantation 
lymphoproliferative disease (PTLD) associated with Epstein-Barr virus infection in 
humans. Santoni et al. demonstrated that PLHV-1 is able to upregulate KSHV 
promoters and transactivate EBV promoters in vitro (243), which suggests that 
molecular interactions between human and porcine gammaherpesviruses might occur 
in vivo. The mode of transmission of PLHV is still unknown making breeding of 
PLHV-free herds challenging as for instance simple weaning of piglets is not 
sufficient (195). Tucker et al., suggested that PLHV-free piglets can be obtained via 
ceasarian-derived and barrier-reared breading procedures (297). 
 
Ø Porcine cytomegalovirus (PCMV) (β-herpesvirus, 
Cytomegalovirus) 
Severity of PCMV infection depends on the age and the immune status of the 
pig and immunity of the sows. In adult pigs, infection is usually unapparent or can 
present subclinical signs (respiratory signs), whereas in piglets and newborn pigs, 
infection induces a generalized infection that is often fatal (76). In a pig-to-baboon 
model of xenotransplantation, Mueller et al. demonstrated that PCMV was 
upregulated in 83% of the animals and PCMV infection was associated with ureteric 
necrosis of one xenograft (Mueller, 4734-40). The susceptibility of PCMV to the 
current antiviral therapy is controversial since one team reported a reduced 
susceptibility of PCMV to these agents (196) whereas another team reported an 
inhibition of PCMV replication (84). No vaccine or specific treatment for PCMV is 
available but early weaning of newborns within the first two weeks after birth and 
isolation of the piglets from other individuals can achieve exclusion of PCMV in 
herds. 
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3.7.3.1.8 Porcine endogenous retroviruses (PERV) (Retroviridae, 
Gammaretrovirus) 
PERV are inheritable viruses and therefore, in contrast to exogenous viruses, 
cannot be excluded from pig herds. While PERV particles were detected in pig cell 
lines derived from leukemias (193), no pig disease has been linked to PERV infection. 
Three classes of replication competent PERV, PERV-A, PERV-B and PERV-C have 
been described (163, 286) and human-tropic PERV are a recombination of PERV-A 
and PERV-C (209). Although it was recognized by Patience et al. that PERV can be 
transmitted to human cells and results in a productive infection in vitro (212), no in 
vivo transmission has been reported in human even 8 years after receiving pig islet 
cells (298). Several strategies have been developed in order to minimize the risk of 
PERV transmission, including: selection of PERV-C-free animals to prevent 
recombination of PERV-A and PERV-C; selection of animal expressing very low 
levels of PERV-A and PERV-B by discriminating high producers, whose PBMC 
produce high amounts of PERV upon stimulation, from low producers (285); 
development of vaccine (82) and finally inhibition of PERV expression by using 
PERV-specific small interfering RNA (siRNA) as well as short hairpin RNA 
(shRNA) and retroviral vectors (70, 143, 189). 
3.7.3.2 Recipient-to-donor transmission 
In this chapter, I will discuss about human viruses that have been reported to 
have interactions with porcine cells. The concerns about the infectious risks have been 
focused predominantly on the transmission of pathogens from animal-to-human, i.e. 
pig-derived infections, and the possibility of human virus infection and destruction of 
transplanted pig organs have been appreciated only recently, which renders the list 
below non exhaustive. 
3.7.3.2.1 Adenoviruses (Adenoviridae) 
Humans infected with adenoviruses display a wide range of responses, from 
no symptoms at all to acute respiratory infections with fever and conjunctivitis 
referred to as epidemic keratoconjunctivitis (EKC). In 1957, Guerin et al. 
demonstrated for the first time that human adenoviruses (hAdV) infect porcine kidney 
cells in vitro (113). More recently, three groups described efficient hAdV replication 
of a few hAdV types (1, 4, 5, and 17) in immortalized porcine cell lines and primary 
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cell cultures of several organs and tissues resulting in complete cytopathic effects 
(108, 138, 160). Swine infected experimentally with hAdV develop lesions in the 
respiratory tract but did not show clinical signs (17). Several studies demonstrated that 
infection of human endothelial cells with hAdV induces an upregulation of adhesion 
molecules and cytokines secretion, causing enhanced leukocyte adhesion and 
transmigration (226, 287). Since interaction of human neutrophils with porcine 
endothelium can cause damages upon stimulation (28), one might speculate that if 
similar modulations occur in hAdV-infected porcine endothelial cells, an increased 
adhesion of human neutrophils to porcine endothelium may then initiate injury to the 
porcine vessel walls and cause xenograft rejection. 
3.7.3.2.2 Coxsackievirus B5 (CVB-5) (Picornaviridae, Enterovirus) 
Humans infected with CVB-5 present symptoms including fever, headache, 
sore throat, gastrointestinal distress as well as chest and muscle pain. 
Coxsackieviruses B are considered to be associated with the pathogenesis of type I 
diabetes (T1D), indeed epidemiological studies have demonstrated that coxsackievirus 
infection is a very frequent event in patients suffering from T1D (92). In 1957, as for 
adenoviruses, Guerin demonstrated for the first time that porcine kidney cells are 
susceptible to CVB-5 in vitro (113). Later, Myers et al demonstrated that i) porcine 
pancreatic islet cells are susceptible to CVB-5 (200), which poses a special concern 
for islet xenotransplantation and that ii) CVB-5-infected porcine pancreatic islet cells 
can transmit the virus to immunosuppressed mice recipients (201). The role of CVB-5 
in clinical xenotransplantation is unclear, thus further studies to investigate CVB5 
infection in mice or nonhuman primates followed by xenotransplantation of 
uninfected pig islets are needed to analyse host-to-graft xenozoonosis as well as 
prophylaxis and antiviral therapies for use in xenotransplantation. 
3.7.3.2.3 Hepatitis C virus (HCV) (Flaviviridae, Hepacivirus) 
HCV acute infection is often asymptomatic, in contrast to chronic infection 
which can lead to cirrhosis or hepatic cancer many years later. In some cases, 
individuals with cirrhosis will develop liver failure, liver cancer or life-threatening 
oesophageal and gastric varices. Two groups demonstrated the susceptibility of 
porcine cells to HCV in vitro (144, 254). In both cell lines, HCV established a 
persistent infection and lysis of infected cells released in supernatants viral particles 
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which were able to infect fresh cultures (254). The difficulty to establish HCV 
infection in cell culture system renders challenging the assessment of infectivity in a 
cross-species model, but studies suggest an infective potential of HCV in porcine 
cells. 
3.7.3.2.4 Influenza virus (Orthomyxoviridae, Influenzavirus A) 
Symptoms of infection with influenza virus include high fever, extreme 
fatigue, body ache and cough. Because of their capacity to be infected by influenza 
viruses from different species (swine, human and avian), the concept of “mixing 
vessels” was proposed for pigs, because viruses can reassort in swine and give rise to 
new, potentially more pathogenic strains (174). As written in chapter 3.7.3.1.1, swine 
are very susceptible to human influenza virus but the infection is usually subclinical. 
In contrast, an in vitro study demonstrated that infection of porcine lung endothelial 
cells with human influenza virus (H3N2) resulted in cytopathic effect appearing 18 
hours post infection and expression of viral proteins (255). Later, Van Poucke et al. 
reported that the pattern of human influenza replication in porcine cells (from the 
entire porcine respiratory tract) resembles that of swine influenza virus (299 7:38). 
These studies suggest that human influenza can induce damage to porcine graft, thus a 
treatment must be established for xenograft recipients. 
3.7.3.2.5 Herpes simplex virus 1 and 2 (HSV-1, HSV-2) 
(Herpesviridae, Simplexvirus) 
Symptoms of herpes simplex virus infection include watery blisters in the skin 
or mucosa of the mouth, lips or genitals, and infection can also have a more severe 
outcome with devastating encephalitis (HSV-1). In a first study, it was reported that 
porcine testis cells were defective for HSV-1 and HSV-2 replication because of a 
defective entry of these viruses. The entry of HSV into porcine testis cells is the 
limiting step of infection (281). However, when porcine cells were expressing the 
herpes virus entry mediator (HVEM) protein after stable transformation, HSV 
binding, entry, replication, and spread was reported (215). Recently, Kim et al. 
demonstrated that porcine kidney epithelial cells are permissive to HSV-1 and HSV-2 
infection, which challenges the previous statements (145). Since no further data is 
available, prophylaxis of HSV infection in xenotransplantation trials should be 
considered. 
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3.7.3.2.6 Human cytomegalovirus (HCMV) (Herpesviridae, 
Cytomegalovirus, β-herpesvirus) 
Infection of HCMV is mainly asymptomatic in immunocompetent hosts and it 
can become life threatening in immunodeficient hosts. As for HSV, HCMV was 
reported to be species specific, however in 2001 Degré et al. demonstrated for the first 
time that a clinical isolate enters and produces viral proteins in porcine endothelial 
cells. Porcine cells were also shown to release infectious viral particles since the 
supernatant of infected cells could infect a second generation of cells (68). More 
recently, Millard et al. extended these findings by using endothelial cells from 
different anatomical origins as well as different HCMV strains. They reported atypical 
cytopathogenic effect, which depends on the vascular origin of the cells, a productive 
infection although less efficient when compared to human endothelial cells and 
induction of apoptosis (185). The group of Seebach and Schneider reported that 
HCMV entry into porcine endothelial cells is sufficient to induce phenotypic changes 
including an increased surface expression of adhesion molecules such as E-selectin 
and vascular cell adhesion molecule 1 (VCAM-1), both critical mediators of 
leukocyte recruitment. An increased expression and shedding of adhesion molecules 
was paralleled by enhanced human leukocyte chemotaxis and adhesion to infected 
pEC cultures (94). The overall effect mediated by HCMV infection of porcine 
endothelial cells seems to have the potential to cause transplantation-associated 
vasculopathy, therefore, a prophylactic treatment approach may be necessary. 
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4 Aims of the study 
Transplantation has emerged as a valid therapy to treat patients with end-stage 
organ failure. However, a major limitation is the increasing shortage of donor organs. 
Xenotransplantation using pig organs is a promising experimental approach to 
increase availability of organs. Clinical pig-to-human trials involving islet cells are 
currently performed. Infection or reactivation of HCMV is the most important 
infectious complication post-transplantation since HCMV infection has been 
associated with allograft rejection and the consequences of HCMV cross-species 
infection of porcine xenografts are still unknown. If xenotransplantation proceeds to 
the clinical stage, understanding the potential role of cross-species CMV infection and 
prevention of porcine cells infection will be a crucial step to ensure safety and optimal 
functioning of the xenograft. 
The molecular basis responsible for HCMV entry into porcine cells remains 
uninvestigated. Given the profound effect of pEC infection with HCMV, knowledge 
of this mechanism is required for interventional strategies. The following aims were 
outlined for this thesis: 
Aim #1: Analyze the involvement of know human entry receptors in HCMV entry 
into pEC and compare them with hEC.  
Aim #2: Determine the involvement of endocytosis, the endosomal pH acidification 
and the cellular cytoskeleton in HCMV entry.  
Aim #3: Analyze the involvement of host species in HCMV nuclear translocation and 
initiation of replication. 
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5 Material and methods 
This section includes material and methods from the manuscript in preparation and 
supplementary protocols. 
5.1 Cells 
SV40-immortalized porcine aortic and bone marrow-derived EC lines (PEDSV.15 
and 2A2, respectively) were established in our laboratory and were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen) supplemented with 10% 
fetal calf serum (FCS), 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine, non-
essential amino acids (1x) (Invitrogen), essential amino acids (1x) (Invitrogen), and 
20 mM HEPES (Invitrogen). Primary human aortic and microvacular EC (HAEC and 
HMVEC, respectively) were obtained from Lonza and were cultured in complete 
EGM-2 medium following the manufacturer’s protocol. The human embryonic lung 
fibroblast cell line (MRC-5) was obtained from ATCC and cultured in DMEM 
medium supplemented with 10% FCS. All cell preparations were tested for 
mycoplasmas by 4, 6-diamidino-2-phenylindole (DAPI) staining. 
5.2 Virus 
HCMV endotheliotropic (TB40/E) and fibrotropic (TB40/F) strains were derived 
from a bone-marrow transplant recipient by 22 passages in EC and fibroblasts, 
respectively (265). For preparation of virus stocks, MRC-5 were infected with 
TB40/E or TB40/F at a multiplicity of infection (MOI) of 0.5. Supernatants of 
infected cultures were harvested at 7 days post infection (dpi) and cleared of cellular 
debris by a 10 minute (min) centrifugation at 2,500 g. Virus stocks were partially 
purified by an ultracentrifugation step over a 15% sucrose cushion (50mM Tris-HCl, 
12mM KCl, 5mM Na2EDTA) at 20,000 rpm for 90 min at 4°C using a SS-34 rotor 
(Beckman Coulter). Virus aliquots were stored at -80°C. The infectious titer was 
determined by TCID50 assays in MRC-5 seeded in 96-well plates (177). All virus 
preparations were tested for mycoplasmas by DAPI staining. 
5.3 Reagents and antibodies 
Heparin, bafilomycin A1, chlorpromazine, dynasore, EIPA (5-N-ethyl-N-
isoproamiloride), filipin, cytochalsin D, nocodazole and acridine orange were 
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obtained from Sigma. The following primary antibodies were used in this study: 
rabbit anti-β1 integrins (Millipore for Western blot), APC conjugated mouse anti-β1 
integrins (Thermo Scientific for flow cytometry, clone MEM-101A), mouse anti-αV 
integrin (Santa Cruz, clone P2W7) and mouse anti-β3 integrin (Santa Cruz, clone 
BV4), PE conjugated mouse anti- PDGFRα (Santa Cruz clone 16A1 for flow 
cytometry), rabbit anti-PDGFRα (Santa Cruz for Western blot), AF488 conjugated 
mouse anti-EGFR (Millipore for flow cytometry, clone LA1), rabbit anti-EGFR 
(Santa Cruz for Western blot), mouse anti-viral glycoprotein B (gB) (Abcam), mouse 
anti-CMV IE72/IE86 (Argene), mouse anti-human β-actin (Sigma), mouse anti-
LAMP2 (BD Pharmingen), mouse anti-EEA1 (BD Transduction Laboratories). 
The following secondary antibodies were used in this study: Alexa Fluor 488 
conjugated goat anti-mouse (Molecular probes), Cy3-conjugated goat anti-mouse 
(Jackson ImmunoResearch) and PE conjugated goat anti-mouse (BD PharMingen). 
5.4 Flow cytometry analysis 
Cells grown in 6-well plates (200,000 cells/well) were incubated for 5 min with PBS-
2nM EDTA, washed and stained for 30 min at 4°C with PE, APC or Alexa Fluor 488-
conjugated monoclonal antibody (mAb) to PDGFRα, β1 integrins and EGFR, 
respectively. The PE or APC-conjugated MOPC21 (BD Pharmingen) and the Alexa 
Fluor 488 conjugated normal mouse IgG (Millipore) were used as isotype-matched 
controls. The fluorescence intensity was measured by using a FACSCanto (BD 
Biosciences) and analysis was performed using FlowJo software (Tree Star). 
5.5 Membrane extractions 
Cells grown in 10 cm Petri dish (300,000 cells/Petri dish) were washed twice, 
scrapped in ice cold PBS and centrifuged 10 min at 2,700 rpm at 4°C. The pellet was 
resuspended in homogenization buffer (500µL/Petri dish, 0.25M sucrose, 0.1M 
K2HPO4, 1mM EDTA) containing 1X protease inhibitors (Roche) and sonicated until 
the cells went from white, cloudy to an opalescent solution. Thereafter, cells were 
centrifuged 15 min at 2,000 rpm at 4°C and the supernatant was centrifuged at 55,000 
rpm for 1 hour at 4°C. The supernatant containing the cytoplasmic proteins was saved 
and the pellet containing the membrane proteins was resuspended in SDS sample 
buffer lacking bromophenol blue. Detection of entry receptors by Western blot was 
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performed from 50µg of proteins and purity of the extraction was assessed by 
detection of tubulin. 
5.6 Detection of MxA proteins after Small interfering RNA 
transfection 
Human EC seeded in 24-well plates (50,000 cells/well) were left untransfected or 
transfected the next day with 31.25ng of non-targeting control siRNA (Ctrl) (Santa 
Cruz) using standard Lipofectamine 2000 protocol (Invitrogen). Alternatively, human 
EC were seeded in 24-well plates and transfected with 12.5ng of SiRNA on the same 
day using standard Hiperfect reagent protocol (Qiagen). 24 hours later cells were 
scraped and lysed (as described below) and the expression of the interferon inducible 
protein MxA was analysed by Western blot. β-actin was used as a loading control. 
5.7 Small interfering RNA assay 
Human EC were transfected in 24-well plates (50,000 cells/well) with 12.5ng of either 
the siRNA to human β1 integrins, PDGFRα or the Ctrl siRNA (Santa Cruz) using 
standard Hiperfect reagent protocol (Qiagen). Twenty-four hours after transfection, 
siRNA-transfected cells were TB40/E- or mock-infected with an MOI of 1. Porcine 
EC seeded in 24-well plates (70,000 cells/well) were transfected the next day with 
31.25ng of the siRNA listed above using standard Lipofectamine 2000 protocol 
(Invitrogen). Twenty-four hours after transfection, siRNA-transfected cells were 
infected with TB40/E at an MOI of 1 for PEDSV.15 cells and 0.5 for 2A2 cells or 
with TB40/F at an MOI of 0.5 and 0.3 for PEDSV.15 and 2A2 cells, respectively. All 
four cell types were then scraped and lysed (as described below) 24 hours post 
infection (hpi). The expression levels of PDGFRα, β1 integrins and the viral 
immediate early (IE) proteins were analysed by Western blot. β-actin was used as a 
loading control. 
5.8 Cell proliferation analysis 
Human EC and porcine EC seeded in 100µl (serum-free medium) per well of a 96-
well plate (3,000 cells/well) were incubated with different inhibitors for 2.5 hours. 
Cells were then washed with PBS to discard the drugs and incubated for another 24 
hours in fresh medium with serum. Cell proliferation was quantified with an 
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AlamarBlue® (Invitrogen) assay following provider’s information. Briefly 10µl of 
AlamarBlue® were added in each well and incubated for another 4 hours at 37°C and 
the absorbance of AlamarBlue® was read with a spectrophotometer (Victor). The 
mean of four independent experiments is shown. 
5.9 Cell cycle progression analysis 
Human and porcine EC seeded in 6-well plates (200,000 cells/well) in serum-free 
medium were treated for 2.5 hours with the different inhibitors, washed with PBS to 
discard the drugs and incubated for another 6.5 hours at 37°C in fresh medium with 
serum. Cells were then trypsinized, washed twice with cold PBS by resuspending and 
spinning down (2,000 rpm, 5min). After the last centrifugation, supernatant was 
discarded and cells were fixed with 70% ice-cold ethanol and incubated overnight at 
4°C. The next day, cells were centrifuged 5 min at 3,000 rpm, the pellet was stained 
for 30 min at 37°C in the dark under gentle shacking with a staining solution (PBS, 
0.3mg/ml of RNAseA, 0.3mg/ml of propidium iodide). After centrifugation (5 min, 
3,000 rpm) cells were resuspended in 100µl of the staining solution and analysed by 
flow cytometry within 24 hours. The fluorescence intensity was measured by using a 
FACSCanto (BD Biosciences) and analysis was performed using FlowJo software 
(Tree Star). One representative experiment out of three is shown. 
5.10 Binding assay 
Human EC and porcine EC grown in 24-well plates (50,000 cells/well) in serum-free 
medium were treated for 1 hour at 4°C with different inhibitors. Cells were then 
infected with TB40/F at an MOI of 5 for 1.5 hours at 4°C in presence of the drugs. As 
a control, TB40/F was preincubated with 100 µg/ml of heparin for 1 hour at 4°C, and 
then added to the cells and incubated for an additional 1.5 hours at 4°C. Cells were 
then washed extensively with ice-cold PBS and lysed as described below. The 
accumulation of the tegument protein pp65 was then analysed by Western blot. β-
actin was used as a loading control. 
5.11 HCMV infection inhibition assay  
Cells grown in 96 well-plates (9,000 cells/well) and in serum-free medium were 
treated with nontoxic doses of various inhibitors for 1 hour at 37°C before being 
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inoculated with TB40/E (MOI of 1 for PEDSV.15 cells and human EC and MOI of 
0.5 for 2A2 cells) or TB40/F at an MOI of 0.5 (PEDSV.15 cells) or 0.3 (2A2 cells) for 
1.5 hours at 37°C. Thereafter, non-internalized viral particles were discarded by 
extensive washes with PBS. Cells were then incubated for 6.5 additional hours at 
37°C. After a fixation step of 10 min in a 80% acetone solution, cells were incubated 
for 1 hour at 37°C with the primary antibody anti-IE (1/500), subsequently incubated 
at 37°C for 1 hour with a Cy3-conjugated goat anti-mouse antibody (1/500), and 
counterstained with DAPI. After each step, the cells were washed three times in PBS. 
The cells were analysed with an IX71 microscope (Olympus). The analyses were 
performed at 20-fold magnification on eight distinct fields. The infection rate was 
then calculated as the mean value of the number of IE positive cells counted on the 
eight distinct fields per condition divided by the mean value of the total number of 
counted cells and multiplied by 100. The mean of four independent experiments is 
shown, otherwise specified in the legends. 
5.12 Measurement of acridine orange intensity after bafilomycin A1 
treatment 
Human EC and porcine EC seeded in 96-well plates (9,000 cells/well) in serum-free 
medium were left untreated or were treated with bafilomycin A1 (2 and 20nM) for 1 
hour. Cells were then incubated with 5 µg/ml of acridine orange diluted in Hank's 
Balanced Salt Solution (HBSS) for 10 min. The acridine orange was removed by three 
washes with PBS and fluorescent pictures were obtained using an IX71 microscope. 
5.13 Co-localization analysis 
Human EC and porcine EC grown in shell vials (Milian) (50,000 cells/shell vial) 
coated with bovine fibronectin (Sigma) were infected with TB40/E or TB40/F at an 
MOI of 5 for 1 hour at 4°C, washed with cold PBS and shifted to 37°C for the 
indicated times. Subsequently, cells were washed three times with PBS and fixed with 
3% paraformaldehyde (Sigma) for 10 min at room temperature, permeabilized 5 min 
with PBS-Triton 0.2%, followed by extensive washes in PBS. Cells were blocked for 
30 min at room temperature with PBS-10% FCS. Glass coverslips staining was 
performed in four steps, each step consisting of a 1-hour incubation at 37°C followed 
by three washes of 5 min with PBS: 1) staining with a primary antibody to gB 
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(1/400), 2) staining with a goat anti-mouse antibody labelled with Cy3 (1/300), 3) 
staining with a primary antibody to EEA1 (1/300) or LAMP2 (1/400), 4) staining with 
a goat anti-mouse antibody labelled with Alexa Fluor 488 (1/300). Cells were then 
counterstained with DAPI (1/10,000) and washed with PBS. Glass coverslips were 
mounted with ProLong® Gold (Invitrogen) and examined under a Leica SP5 confocal 
microscope. Colocalization of red and green signal was determined, using the 
colocalization Test plugin JACoP from ImageJ to calculate Pearson’s coefficient. The 
mean of Pearson’s coefficient was calculated from three independent experiments. 
5.14 Analysis of nuclear translocation of the tegument protein pp65 
Human EC and porcine EC seeded on glass coverslip in shell vials (70,000 cells/well) 
were infected with TB40/E or TB40/F at an MOI of 1 for different periods of times. 
Cells were then washed and fixed with a mixture of ice-cold ethanol/acetone (2:1) for 
10 min, washed with PBS and let air-dried. Coverslips fixed to a slide were incubated 
for 1 hour at 37°C with the primary antibody anti-pp65 (1/500), subsequently 
incubated at 37°C for 1 hour with an AlexaFluor 488-conjugated goat anti-mouse 
antibody (1/300), and counterstained with Evans Blue cytoplasmic staining. After 
each step, the cells were washed three times in PBS. The cells were analysed with an 
IX71 microscope and the analyses were performed at 100-fold magnification. 
5.15 Analysis of the tegument protein pp65 accumulation in TB40/E- 
and TB40/F-infected EC 
Human EC and porcine EC seeded in 24-well plates (70,000 cells/well) were infected 
with TB40/E or TB40/F at an MOI of 1 for different periods of time. Cells were then 
washed and lysed as described below. The accumulation of the tegument protein pp65 
was then analysed by Western blot. β-actin was used as a loading control. 
5.16 Time course of infection  
Human EC and porcine EC grown in 48-well plates (50,000 cells/well) were infected 
with TB40/E or TB40/F at an MOI of 1 for 1h at 4°C, washed with cold PBS and then 
shifted to 37°C for different periods of time. EC were washed and treated with 
trypsin-EDTA (0.25% trypsin and 5 mM EDTA) for 5 min to remove the bound but 
non-internalized virus, washed, and total DNA was extracted following the 
manufacturer’s specifications (Qiagen, DNeasy Blood & Tissue Kit). DNA 
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concentration was measured with the Nanodrop and 30ng of total DNA was 
quantified using specific primers and probes for a 62 bp region of the glycoprotein B 
gene (UL55) as previously described (324). Amplification was performed in a Real-
Time thermocycler (iQ5 Cycler; Bio-Rad) as follows: 13min 30s at 95°C and 50 
cycles of 15s at 95°C and 60s at 60°C. Each reaction was done in duplicate, and each 
point represents the average +/- standard deviation (SD) of one representative 
experiment. 
5.17 Analysis of the initiation of replication in TB0/E- and TB40/F-
infected EC 
Human EC and porcine EC seeded in 24-well plates (70,000 cells/well) were infected 
with TB40/E or TB40/F at an MOI of 1 for different periods of time. Cells were then 
washed and lysed as described below. The expression of the IE proteins was then 
analysed by Western blot and β-actin was used as a loading control.  
5.18 Analysis of the involvement of FAK in HCMV entry into human 
EC 
Human EC seeded in serum-free medium in 24-well plates (70,000 cells/well) were 
infected with TB40/E or TB40/F at an MOI of 3 for different periods of time (10, 30 
and 60 min). As a positive control, cells were incubated for 5 min with PBS 
supplemented with 20% FCS. Cells were then washed and lysed as described below. 
The expression of FAK (Santa Cruz, dilution 1/200) and the phosphorylated form of 
FAK (Invitrogen, dilution 1/1000) was analysed by Western blot and β-actin was used 
as a loading control.  
5.19 Western blot analysis 
Cultures grown in 24 well plates were scraped and lysed directly in SDS sample 
buffer (63 mM Tris HCl, 10% Glycerol 2% SDS, 0.0025% Bromophenol Blue, pH 
6.8). Protein samples were separated by electrophoresis on a 10% polyacrylamide gel 
and transferred to a polyvinylidene difluoride membrane (Hybond-P, GE Healthcare). 
After blocking with 5% non-fat dried milk (Bio-Rad) in 2% Tween/TBS, membranes 
were incubated overnight with primary antibody at 4°C, followed by a 1-hour 
incubation with a horseradish peroxidase-conjugated secondary antibody (GE 
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Healthcare, 1/5000). The targeted proteins were revealed by enhanced 
chemiluminescence using the ECL reagent (GE Healthcare). One representative 
experiment out of three independent experiments is shown, otherwise specified in the 
legends. 
5.20 Statistical analysis 
All values are reported as mean values ± SD. Statistical analysis were performed 
using the unpaired Student t test with Prism GraphPad software, with statistically 
significant differences set as: *p< 0.05, **p < 0.01,***p < 0.001,****p < 0.0001. 
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6 Results 
The results section of this thesis is divided into 3 main parts corresponding to the 
three main steps of HCMV entry into target cells: 
- The first part focuses on the role of the different receptors, 
- The second part investigates mechanisms of virus internalization by target 
cells, 
- The third part elucidates nuclear translocation of the virus following 
internalization and the initiation of viral replication. 
 
A manuscript has been prepared and submitted for publication. 
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6.1 Molecular basis of HCMV entry into porcine endothelial cells 
6.1.1 Cell surface expression of HCMV entry receptors 
To enter human cells (mainly fibroblasts, epithelial and endothelial cells), 
HCMV utilizes different cellular receptors such as PDGFRα and EGFR and co-
receptors including β1, αV and β3 integrin subunits (34, 81, 272, 307, 308). Data on 
the requirement of these receptors and co-receptors is controversial (131, 301), and 
dependent on the cell type studied. HAEC, HMVEC, PEDSV.15 and 2A2 cells were 
first analysed by flow cytometry for the surface expression of β1, αV, β3 integrins, 
EGFR and PDGFRα. All four cell types exhibited high levels of β1 integrins and no 
EGFR, whereas PDGFRα  and  αV and  β3  integrin subunits were detected only on 
hEC, with a weaker β3 integrin subunit expression observed on HAEC compared to 
HMVEC (Fig. 4).  
 
 
Fig. 4: Comparative surface expression of HCMV entry receptors and co-receptors on 
human and porcine EC. hEC and pEC were harvested and the surface expression of HCMV 
entry receptors was analysed by flow cytometry (Grey filled histograms: control isotype, 
Black line histograms: indicated receptor). HAEC: human aortic EC, HMVEC: Human 
dermal microvascular EC, PEDSV.15: porcine macrovascular aortic EC, 2A2: porcine 
microvascular bone-marrow derived EC. One representative experiment is shown out of three 
independent experiments. 
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In the absence of antibodies specific for porcine entry receptors, flow 
cytometry analysis for PDGFRα, β1 integrin subunit and EGFR was conducted with 
anti-human monoclonal antibodies expected to be cross-reactive, based on the protein 
sequence. To determine if the lack of detection of entry receptors on pEC surface was 
due to missing cross-reactivity of these antibodies, Western blot analysis of pEC total 
extracts was performed using anti-human polyclonal antibodies (Fig. 5A). PDGFRα 
was detected in both types of pEC whereas EGFR was only detected in 2A2 cells. In 
order to determine the location of these receptors, we conducted membrane extraction 
and analysed the expression of PDGFRα and EGFR in the different fractions. 
PDGFRα was detected in the membrane fraction of both pEC whereas EGFR was 
detected only in the membrane fraction of 2A2 cells (Fig. 5A). In order to exclude the 
possibility of the expression of a truncated but functional EGFR on PEDSV.15 cells, 
cells were stimulated with EGF (100µg/ml) for 10 min and the activation of EGFR 
signaling pathway was assessed by the detection of the phosphorylated form of Akt in 
total extracts by Western blot. The treatment of PEDSV.15 cells with EGF failed to 
activate the EGFR signaling pathway represented by the absence of the 
phosphorylated form of Akt although the non-phosphorylated form was detected, 
whereas the stimulation of 2A2 cells induced the phosphorylation of Akt, which 
suggests that PEDSV.15 cells do not express EGFR (data not shown). 
Concerning αV and β3 integrin subunits, both antibodies were anti-human 
polyclonal antibodies. In order to exclude any incompatibility of the antibodies with 
the flow cytometry technique resulting in the absence of detection of αV and β3 
integrin subunits, their expression was as well analysed by Western blot in the total 
extracts, cytoplasmic and membrane fractions of pEC. αV integrin subunit was 
detected in the total extract and the membrane fraction of 2A2 cells and to a lesser 
extend in the total and membrane fractions of PEDSV.15 cells. A weak expression of 
β3 integrin subunit was detected in the membrane fraction of 2A2 cells but was absent 
in total and membrane extracts of PEDSV.15 cells (Fig. 5B). 
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Fig. 5: Localisation of HCMV entry receptors and co-receptors in pEC by Western blot. 
pEC membrane fractions were prepared and the extracts were analysed for the expression of 
(A) PDGFRα, EGFR and (B) αV and β3 integrin subunits. Total: total extract, cytopl.: 
cytoplasmic fraction, Mb.: membrane fraction. One representative experiment out of two 
independent experiments is shown. 
 
All together, these results show that similarly to hEC, pEC express a panel of 
HCMV entry receptors and co-receptors. The next step was then to assess whether 
HCMV is utilizing these receptors to enter pEC, similarly to the entry into hEC. 
 
Table 3: Table recapitulating the expression of the different receptors and co-receptors on 
hEC and pEC.  
 
 2A2 PEDSV.15 HMVEC HAEC 
PDGFRα  yes yes yes yes 
EGFR yes NO NO NO 
αV integrins yes yes yes yes 
β1 integrins yes yes yes yes 
β3 integrins yes NO yes yes 
 
6.1.2 Involvement of PDGFRα  and β1  integrin subunit in HCMV 
entry into pEC 
First, proper transfection conditions, i.e. non-interferon (IFN) inducing 
conditions were set up for hEC. The liposomal transfection reagent used for pEC 
transfection, lipofectamine2000, has been reported to induce, in human cells, Type I 
interferon (IFN-I) and its inducible proteins (165). Type I IFNs are a highly regulated 
defense system against viral infection (197) and once produced, they induce an up-
regulation of direct antiviral effectors including amongst others the myxovirus protein 
A (MxA) (5, 99). The literature has reported that high levels of type I IFN are critical 
early defense mechanisms against CMV infection (111, 178, 179). In my setting, 
transfection with lipofectamine2000 resulted in the production of MxA protein by 
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HAEC in irrelevant control short interfering RNAs (SiRNA)-transfected hEC but not 
in untransfected cells (Fig. 6A), preventing subsequent HCMV infection revealed by 
the absence of IE proteins in HAEC transfected cells 24 hpi (data not shown). 
Therefore, hEC were transfected with Hiperfect (Qiagen), another transfection 
reagent, suggested to lack the IFN inducing effect because of the reduced amount of 
SiRNA needed for transfection compared to lipofectamine2000. After transfection of 
HAEC with a control SiRNA, no MxA protein was detected showing that in these 
conditions, type I IFN is not or weakly induced by the transfection reagent (Fig. 6B). 
 
Fig. 6: Induction of MxA protein expression in SiRNA transfected EC. (A) PEDSV.15, 
2A2 cells and HAEC were left untransfected or transfected with a mixture of 
lipofectamine2000 and a control SiRNA (SiCtrl) and the expression of MxA protein was 
assessed 24 hours after transfection. As a positive control, HAEC were treated with 100U/ml 
IFNβ. (B) HAEC were either left untransfected (Unt.) or transfected with a mixture of 
Hiperfect and SiCtrl and the expression of MxA protein was assessed 24 hours after 
transfection. As a positive control, HAEC were treated with 100U/ml IFNβ. β-actin was used 
as a loading control. One representative experiment is shown. 
 
As expression of β1 integrins and PDGFRα was common to all four cell types, 
I then evaluated their involvement in entry of both TB40/E and TB40/F. hEC and 
pEC transfected with a SiCtrl or SiRNA specific for β1 integrins (Fig 7) or PDGFRα 
(Fig 8), were infected with either TB40/E (hEC and pEC) or TB40/F (only pEC), and 
the expression of IE proteins was assessed 24 hpi by Western blot. The consequence 
of the silencing of receptors on TB40/F infection of hEC could not be assessed since 
fibrotropic HCMV strains do not translocate to the nucleus of hEC, a prerequisite for 
initiation of viral replication, and therefore hEC do not express IE proteins (265). In 
both HAEC and HMVEC, silencing of the β1 integrin subunit resulted in a decreased 
expression of IE proteins compared to cells transfected with an irrelevant SiCtrl, 
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confirming the involvement of β1 integrins in HCMV entry into hEC (81). SiRNA 
being designed for human cells, silencing of β1 integrins was less efficient in pEC 
when compared to hEC. As a consequence, the effect of silencing on HCMV infection 
was not optimal. When PEDSV.15 cells were silenced for β1 integrin subunit 
expression, a decreased expression of IE proteins was observed in both TB40/E- and 
TB40/F-infected PEDSV.15 cells. Surprisingly, silencing of β1 integrins in 2A2 cells 
did not result in a decreased IE protein expression in both TB40/E- and TB40/F- 
infected 2A2 cells (Fig. 7). 
 
 
Fig. 7: Incidence of silencing of β1 integrin subunit expression on entry into EC of two 
strains of HCMV. hEC and pEC were transfected with either control SiRNA (SiCtrl) or β1 
integrins SiRNA. Cells were infected 24h post-transfection and IE expression was assessed 24 
hpi by Western Blot. β-actin was used as a loading control. One representative experiment out 
of three is shown. 
 
Silencing of PDGFRα in both pEC resulted in a decreased expression of IE 
proteins 24 hpi in both TB40/E- and TB40/F-infected cells, although the inhibition 
was weaker in TB40/F- compared to TB40/E-infected PEDSV.15 cells. In contrast, 
silencing of PDGFRα did not modulate IE protein expression in TB40/E-infected 
hEC, which supports the literature demonstrating that PDGFRα might not be involved 
in HCMV entry into hEC (301) (Fig. 8). It is noteworthy to mention that both hEC 
display a weak expression of PDGFRα compared to both pEC, which would explain 
why silencing of PDGFRα does not affect HCMV infection of hEC. 
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Fig. 8: Incidence of silencing of PDGFRα  expression on entry into EC of two strains of 
HCMV. hEC and pEC were transfected with either control SiRNA (SiCtrl) or PDGFRα 
SiRNA. Cells were infected 24h post-transfection and IE expression was assessed 24 hpi by 
Western Blot. β-actin was used as a loading control. One representative experiment out of 
three is shown. 
 
The assessment of the involvement of αV and β3 integrin subunits in HCMV 
entry into hEC and pEC was more challenging. Indeed, depending on the SiRNA 
used, the transfection conditions are rather unlikely to stay consistent between two 
different SiRNAs and as a consequence, a condition optimal for one specific SiRNA 
might not be ideal for another SiRNA. It was also documented that SiRNA vary 
markedly in their gene-silencing efficacy. These two complications rendered the 
silencing of αV and β3 integrin subunits very challenging. Despite several attempts, I 
was not able to select an effective SiRNA sequence targeting the expression of αV 
and β3 integrin subunits. Therefore, I was not able to confirm the involvement of αV 
and β3 integrin subunits in HCMV entry into hEC and to assess their role in HCMV 
entry into pEC. 
6.2 Analysis of the mechanisms of HCMV internalization 
6.2.1 Involvement of endocytosis in HCMV internalization 
6.2.1.1 Incidence of specific inhibitors of endocytosis on cell 
proliferation, cell cycle progression and HCMV binding 
In order to investigate potential HCMV entry pathways in pEC and compare 
them with the entry mechanisms used by HCMV to enter hEC, I used agents that are 
known to inhibit the various endocytic pathways. It is to be noted that some of the 
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agents used in this study also have other functions than inhibiting endocytosis. In my 
settings, I treated the cells prior to infection and the drugs were removed after 1h30 
min of infection compared to the literature were drugs were left the entire duration of 
the experiment (8 or 20 hours) or later during infection to investigate processes 
subsequent to virus entry (238). In my settings I assumed that the main effect of the 
drugs would be linked to virus entry, therefore I referred to these drugs as inhibitors 
of entry. I first determined the toxicity of inhibitors of the clathrin-mediated 
endocytosis (chlorpromazine), the lipid rafts (filipin), the dynamin 2-dependent 
pathways (dynasore) and macropinocytosis (EIPA) by a proliferation assay 
(AlamarBlue® assay) and a cell cycle arrest assay (Fig. 9 and 10, respectively). For 
the proliferation assay, cells were treated for 2.5 hours, washed and incubated for 
another 24h in fresh medium. The next day proliferation was assessed with an 
AlamarBlue® assay. The drug treatment did not affect cell proliferation, represented 
by a similar proliferation capacity of treated cells compared to untreated cells (Fig. 9). 
For the cell cycle arrest assay, cells were treated as for the inhibition assay described 
in chapters 6.2.1.2 and 6.2.1.3: briefly, cells were treated for 2.5 hours with the 
different inhibitors, then washed, and incubated for another 6.5 hours in fresh 
medium. Cells were then fixed, stained with propidium iodide and analysed by flow 
cytometry. As a positive control, cells were treated with nocodazole during the 
duration of the experiment (9 hours). Nocodazole is an agent that binds free tubulin 
subunits, preventing the incorporation of tubulin in microtubules and therefore 
preventing microtubules polymerization, which induces a stop in the G2/M phase. 
The percentage of cells in each cell cycle phase varied from one cell type to another, 
however no significant differences in the cell repartition in each phase was observed 
between untreated and treated cells, indicating that the doses used in this study do not 
stop the cell cycle progression. As expected, when cells were treated with nocodazole, 
most of the cell population was blocked in the G2/M phase. As an example, in 2A2 
cells, 77.4% of cells were in the G2/M phase when treated with nocodazole as 
compared to 15.8% for untreated cells (Fig. 10). To rule out that the absence of effect 
of the different inhibitors observed at 8h post treatment was due to an insufficient 
time for the cells to proliferate, the same experiment was carried out with a longer 
incubation time in fresh medium. Therefore, in a second experiment, cells were 
incubated for 24h after treatment and the repartition in the cell cycle was analysed. 
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After 24h, no modulation was observed confirming the non-toxicity of the inhibitors 
(data not shown). 
 
 
 
Fig. 9: Analysis of the effect of the different inhibitors of endocytosis on cell 
proliferation. hEC and pEC were treated with the different inhibitors and the proliferation 
was assessed by an AlamarBlue® assay. 
 
 
 
Fig. 10: Incidence of the inhibitors of endocytosis on cell cycle progression. hEC and pEC 
were treated with the different inhibitors for 2.5 hours and the cell cycle progression was 
assessed 8h later by flow cytometry. 
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An additional study was undertaken to investigate whether the inhibitors of 
endocytosis used in this study affect virus binding. Indeed, a potential effect of these 
drugs could result in altering virus binding by downregulation of the expression of 
receptors (chlorpromazine has been shown to downregulate receptor recycling (306)). 
Cells pre-treated with the different inhibitors were infected with TB40/F and the 
accumulation of the tegument protein pp65 was analysed by Western blot. Pre-
treatment of hEC and pEC with chlorpromazine (C), dynasore (D), filipin (F) and 
EIPA (E) did not modulate the accumulation of pp65 when compared to untreated 
cells (U). As a control for inhibition of binding capacities of viral particles, TB40/F 
was pre-incubated with heparin (100µg/ml) and as expected, almost no pp65 was 
detected (Fig 11). It is noteworthy to mention that binding was only assessed for 
TB40/F and not for TB40/E because almost no pp65 is detected in TB40/E-infected 
EC (discussed in chapter 6.3.2); however it is known that the tropism of the virus does 
not modulate binding capacities of HCMV (265) and as a consequence, I assumed that 
the binding capacity of both strains was similarly modulated by the different drug 
treatments. 
 
Fig. 11: Effect of inhibitors of endocytic pathways on HCMV binding. hEC and pEC were 
pre-treated with different inhibitors and infected for 1h at 4°C to allow binding and the viral 
tegument protein pp65 was detected by Western blot. As a control, HCMV was preincubated 
with heparin (100µg/ml). β-actin was used as a loading control. H: heparin, U: untreated, C: 
chlorpromazine, D: dynasore, F: filipin and E: EIPA. 
 
6.2.1.2 Implication of endocytic pathways and lipid rafts in entry 
into hEC and pEC of the endotheliotropic strain TB40/E 
A number of different internalization and trafficking pathways are utilized by 
animal viruses to enter host cells. The best documented ones include direct fusion at 
the membrane, endocytosis involving lipid rafts, clathrin-mediated endocytosis and 
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uptake via caveolae (both dependent on the activity of a large GTPase, dynamin-2, for 
the release of endocytic vesicle from the plasma membrane (63, 120, 208)), 
macropinocytosis and phagocytosis (182, 258). Caveolae-mediated endocytosis 
transports very small cargos since the diameter of caveolin-coated vesicles can only 
reach up to 100 nm. The HCMV diameter being around 200 to 300 nm, I reasoned 
that regarding the size of the vesicles and viral particles, caveolae-mediated 
endocytosis might not likely be involved in HCMV entry into EC.  
 
 
Fig. 12: Scheme illustrating the different endocytic pathways involved in virus entry (adapted 
from Chou et al. (45)). 
 
HAEC, HMVEC, PEDSV.15 and 2A2 cells pre-treated with nontoxic dose of 
inhibitors determined in the previous chapter were infected at different MOI in order 
to have the same percentage of IE expressing cells: an MOI of 1 for HAEC, HMVEC 
and PEDSV.15 cells and an MOI of 0.5 for 2A2 cells since these cells are more 
sensitive to infection (185). Entry was then assessed by the expression of IE proteins 
by immunofluorescence 8 hpi (Fig. 13A). When EC were treated with dynasore, a 
molecule interfering in vitro with the GTPase activity of dynamin 2 (175), the 
expression of IE proteins was inhibited by about 80% for all four cell types, 
suggesting that, similarly to hEC, TB40/E entry into pEC is dynamin 2 dependent. 
Because I observed a strong inhibition with all the four cells types, as a control for 
specificity of dynasore, the same experiment was conducted with human fibroblasts 
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(MRC-5) in which HCMV enters via direct fusion of the viral envelope with the 
plasma membrane (54), thus dynasore is not expected to have any effect on infection. 
As expected, no inhibition of the expression of IE proteins in dynasore-treated 
compared to untreated MRC-5 was observed (Fig 13B). To assess the involvement of 
clathrin-mediated endocytosis, the specific inhibitors chlorpromazine, a cationic 
amphiphilic drug that causes clathrin to localize and accumulate in late endosomes 
(306), was used. When EC were treated with chlorpromazine, a moderate inhibition of 
about 20% for 2A2 cells, 30% for HMVEC and 40% for PEDSV.15 cells and HAEC 
was observed. When cells were treated with the inhibitor of macropinocytosis EIPA, 
an inhibitor of Na(+)/H(+) exchanger, an inhibition of 30% was observed for 2A2 
cells and at least 40% for HAEC, HMVEC and 2A2 cells (Fig. 13A). These findings 
demonstrate that similar to entry into hEC, TB40/E enters pEC by a dynamin-2 
dependent mechanism and macropinocytosis. However, despite taking care to remove 
all drugs we cannot completely exclude some remaining effects which could affect 
post-entry, which are irreversible despite removal. One direct assay to assess the 
effect of the drugs on entry would be to quantify the viral genome delivered in the 
cytoplasm. 
Lipid rafts, also referred to as microdomains, are highly dynamic structures of 
the plasma membrane that contain high concentration of cholesterol and 
glycosphingolipids. Membrane proteins involved in cell signalling have been 
observed in these microdomains, leading to the consent that lipid rafts play a role in 
signalling transduction (reviewed in (261)). These membranes proteins include 
amongst others EGFR and PDGFR (169, 188). Regarding HCMV infection, Wang et 
al. demonstrated that lipid rafts have an important role in regulating the interaction 
between EGFR and αVβ3 integrin and its signalling pathway, leading then to virus 
internalization. One approach for studying the function of lipid rafts involves 
depleting cells of cholesterol. Interactions between cholesterol and sphingolipids are 
important for holding lipid raft structures together, therefore the integrity of these 
microdomains can be disrupted by treating cells with certain agents such as filipin 
which binds to and sequester cholesterol. I assessed whether the removal of 
cholesterol from the plasma membrane and indirectly the disruption of lipid rafts 
impacts TB40/E entry into pEC.  After treating the cells with filipin, I observed an 
inhibition of IE expression between 40 and 45% and 30% for hEC and pEC, 
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respectively, suggesting an involvement of lipid rafts in TB40/E entry into EC (Fig. 
13C). 
 
 
Fig. 13: Comparison of the incidence of the treatment of inhibitors of endocytosis on the 
endotheliotropic strain TB40/E entry into hEC and pEC. EC were pretreated for 1h with 
various drugs inhibiting (A) endocytosis and phagocytosis (dynasore), clathrin-mediated 
endocytosis (chlorpromazine) or macropinocytosis (EIPA) or (C) lipid rafts (filipin) and were 
inoculated with TB40/E. (B) Human fibroblasts (MRC-5) were pretreated for 1h with 
dynasore and infected with TB40/E. Infection was assessed by detection of IE proteins at 
8hpi. *: <0.05, **: <0.001, ***: <0.003, ****: <0.001. One representative experiment is 
shown for MRC-5. 
 
6.2.1.3 Implication of endocytic pathways and lipid rafts in entry 
into hEC and pEC of the fibrotropic strain TB40/F 
Sinzger et al. demonstrated that contrary to endotheliotropic HCMV strains 
(e.g. TB40/E), fibrotropic strains do not translocate to the nucleus of hEC and 
consequently cannot initiate viral replication (265). The expression of IE proteins 
being the main readout, I was able to assess the implication of endocytic pathways in 
TB40/F-infected pEC. When pEC were treated with dynasore, an inhibition >80% 
was observed for both cell types suggesting that TB40/F entry into pEC is dynamin 2 
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dependent (Fig. 14A). As previously, the pre-treatment of MRC-5 with dynasore did 
not inhibit IE expression (Fig. 14B). When pEC were treated with chlorpromazine, no 
effect on IE protein expression was observed, suggesting that TF40/F entry does not 
occur through a clathrin-dependent pathway. When pEC were treated with EIPA, IE 
protein expression was inhibited by less than 20% for both 2A2 cells and a non-
significant inhibition of the expression of IE proteins was observed for PEDSV.15 
cells, suggesting that macropinocytosis is involved to a lesser extent in TB40/F entry 
into pEC (Fig. 14A). When cells were treated with filipin, no significant inhibition 
was observed suggesting that entry of TB40/F into pEC does not require lipid rafts 
(Fig. 14C). These results suggest that to enter pEC, TB40/F uses mainly a dynamin-2 
dependent mechanism and lipid rafts are not involved. 
 
Fig. 14: Comparison of the incidence of the treatment of inhibitors of endocytosis on the 
fibrotropic strain TB40/F entry into hEC and pEC. pEC were pre-treated for 1h with 
various drugs inhibiting (A) endocytosis and phagocytosis (dynasore), clathrin-mediated 
endocytosis (chlorpromazine) or macropinocytosis (EIPA) or (C) lipid rafts (filipin) and were 
inoculated with TB40/F. (B) Human fibroblasts (MRC-5) were pretreated for 1h with 
dynasore and infected with TB40/F. Infection was assessed by detection of IE proteins at 
8hpi. *: 0.05, ****: <0.001. One representative experiment is shown for MRC-5. 
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6.2.2 Involvement of the endosomal pH acidification in entry of 
both HCMV strains 
Immediately following internalization by endocytosis, the acidification of 
endocytic vesicles triggers a conformational change in the viral glycoproteins and the 
release of the viral capsid into the cytoplasm. Some viruses also enter cells in a pH-
independent manner via direct fusion of their envelope with the plasma membrane. 
Depending on the cell type, HCMV has the capability to use these two distinct 
mechanisms. I thus evaluated the importance of the endosomal pH acidification in the 
release of HCMV capsids in the cytoplasm by treating the cells with an inhibitor of 
the vacuolar H+-ATPase (bafilomycin A1, BafA1) (321). First, as for the inhibitors of 
the different endocytic pathways, the toxicity of BafA1 on cell proliferation and cell 
cycle progression was evaluated. As for the previous inhibitors, BafA1 did not inhibit 
proliferation neither it blocked the cell cycle progression (Fig 15A and B). I then 
evaluated whether EC pre-treatment with BafA1 prevented HCMV binding, and as 
previously, the drug did not have any effect on virus binding (data not shown). The 
next step was to ensure that the concentration of BafA1 used in the experiment 
inhibited the acidification of the intracellular acidic vesicles. For this purpose, EC 
were stained with acridine orange following treatment with or without BafA1 and 
visualized under a fluorescence microscope. The emission spectrum of acridine 
orange (AO) depends on the local concentration of the compound. AO is green in the 
nucleus whereas in acidic compartments it gets protonated and sequestered. In these 
low pH conditions, AO will emit orange light when excited with blue light. Figure 
15C shows EC that were incubated with acridine orange. The figure shows that the 
red fluorescence representing the acidic vesicles disappeared when EC were treated 
with 20 nM of BafA1. This result confirms that 20 nM of BafA1 are enough to inhibit 
endosomal acidification. To assess whether endosomal pH acidification is required in 
the release of HCMV capsids in the cytoplasm, hEC and pEC pretreated with BafA1 
were infected with TB40/E (pEC and hEC) or TB40/F (pEC only) and IE expression 
was evaluated 8 hpi by immunofluorescence. In both TB40/E-infected pEC, pre-
treatment with BafA1 resulted in an inhibition of IE expression of 30 and 50% for 
2A2 cells and PEDSV.15 cells, respectively. Similar results were observed with hEC, 
suggesting that TB40/E entry into hEC and pEC involved endosomal pH acidification 
(Fig. 15D). An inhibition of 30% was observed in TB40/F-infected PEDSV.15 cells 
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suggesting a relative involvement of the pH in TB40/F entry into these cells. 
Surprisingly, pretreatment of 2A2 cells with BafA1 resulted in an inhibition of only 
15%, suggesting that in these cells, pH acidification is dispensable for TB40/F entry 
into 2A2 cells. 
 
Fig. 15: Comparison of the involvement of the endosomal pH acidification in the entry 
into hEC and pEC of the endotheliotropic TB40/E and the fibrotropic TB40/F strains. 
hEC and pEC were treated with bafilomycin A1 (BafA1) and (A) the proliferation or (B) the 
cell cycle progression were assessed. Noco (9h): Nocodazole treated cells for 9h. (C) hEC 
and pEC treated or not with BafA1 (2 or 20nM) for 1 hour were incubated in medium 
containing 5 µg/ml of acridine orange for 10 min. The acidic compartments are presented as a 
red staining in the untreated EC. (D) Cells were pretreated for 1h with a drug inhibiting 
endosomal pH acidification (Bafilomycin A1) and were inoculated with TB40/E or TB40/F. 
Infection was assessed by detection of IE at 8hpi. *: <0.05, **: <0.001. (C) One 
representative experiment out of two is shown. 
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6.2.3 Involvement of the actin and microtubule cytoskeleton in 
HCMV internalization and translocation 
It has been reported that HCMV entry into epithelial and endothelial cells is 
actin dependent (19). Entry and trafficking of herpesvirus in general was shown to be 
dependent on both the actin and the microtubule cytoskeleton, which cooperate in 
order to deliver the viral genome to the nucleus of infected cells (173). I thus assessed 
whether HCMV entry into pEC also requires an intact actin (Fig. 16) and microtubule 
(Fig. 17) cytoskeleton. I used cytochalasin D, a pharmacological inhibitor that binds 
to actin barbed ends, which consequently blocks polymerization and depolymerisation 
at the plus end. I analysed the effects of this inhibitor on HCMV infection. First, the 
toxicity and the effect of this inhibitor on HCMV binding were assessed. Cytochalasin 
D did not inhibit cell cycle progression and no inhibition of binding was observed 
(data not shown). Besides, we evaluated whether the concentration used was equally 
active in hEC and pEC. To do so, I stained the pre-treated cells with phalloidin (a 
toxin know to bind fibrous actin) and looked at the structure of the actin cytoskeleton. 
For all four cell types, the cytochalasin D pre-treatment resulted in a disassembly of 
the actin cytoskeleton represented by the absence of a fibrous actin staining (data not 
shown). HAEC, HMVEC, PEDSV.15 cells and 2A2 cells pre-treated with 
cytochalasin D were infected with TB40/E (Fig. 16A) or TB40/F (Fig. 16B), and 
entry was assessed by the expression of IE proteins by immunofluorescence 8 hpi. 
When pre-treated with cytochalasin D, infection with TB40/E of HAEC and HMVEC 
was completely inhibited as assessed by a nearly 100% reduction of IE protein 
expression, confirming that actin remodelling is essential for HCMV entry into EC. 
After pre-treatment of 2A2 cells and PEDSV.15 cells, an inhibition of 70% and only 
35% was observed, respectively, this suggests that an intact actin cytoskeleton is 
required for entry of TB40/E into 2A2 cells but dispensable for entry into PEDSV.15 
cells (Fig. 16A). In contrast, when pre-treated 2A2 cells and PEDSV.15 cells were 
infected with TB40/F, no inhibition of IE expression was observed, suggesting that in 
these conditions, TB40/F enter pEC in an actin-independent manner (Fig. 16B). 
Because of the weaker effect of cytochalasin D on the inhibition of pEC infection 
with HCMV, we analysed the consequences of cytochalasin D treatment on fibrous 
actin by phalloidin staining. After treatment with cytochalasin D, we observed a 
conversion of F-actin from long fibers in untreated 2A2 to punctate structures in 
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treated 2A2 (Fig. 16C), confirming the effectiveness of the cytochalasin D in 2A2. 
Similar results were obtained with PEDSV.15 (data not shown). 
To investigate the involvement of the microtubule cytoskeleton in HCMV 
entry / nuclear translocation, I used nocodazole, which prevents microtubule 
polymerization. As for cytochalasin D, the toxicity and the effect on HCMV binding 
capacity after treatment with nocodazole was assessed. For the cell cycle arrest assay, 
EC were treated with nocodazole for 2h30 (1 hour pre-treatment followed by a 1h30 
treatment with the virus) (in contrast to the positive control where a lower dose of 
nocodazole is incubated for the duration of the entire experiment, i.e. 9h) then washed 
and incubated with fresh medium for 6h30. The 2h30 treatment did not inhibit 
proliferation or stop the cell cycle progression neither did it prevent virus binding 
(data not shown). I then assessed the impact of such treatment on HCMV infection. 
HAEC, HMVEC, PEDSV.15 cells and 2A2 cells pre-treated with nocodazole were 
infected with TB40/E (Fig. 17A) or TB40/F (Fig. 17B), processed and analysed as 
previously described. When HAEC and HMVEC were pre-treated with nocodazole, 
an inhibition of IE expression of 90% and 65% was observed, respectively, 
confirming the involvement of microtubules in the nuclear translocation of viral 
capsid. An inhibition of 70% was observed in treated PEDSV.15 cells, suggesting as 
well an involvement of microtubules in TB40/E nuclear translocation. In contrast, a 
weak inhibition of ~20% was observed in 2A2 cells, suggesting that in these cells, an 
intact microtubule cytoskeleton might not be necessary for trafficking (Fig. 17B). An 
inhibition of 30% was observed in TB40/F-infected PEDSV.15 cells suggesting a 
partial involvement of microtubules in translocation. In contrast, an inhibition <10% 
was observed for 2A2 cells, suggesting that microtubules are not involved in 
trafficking of TB40/F particles in 2A2 cells. As previously, we confirmed the 
effectiveness of nocodazole treatment of pEC on microtubule organization by a 
tubulin staining. In untreated 2A2, tubulin staining showed a normal tubular 
microtubule organization. In contrast, in nocodazole treated 2A2, the tubular structure 
was absent (Fig. 17C), confirming the effectiveness of nocodazole in 2A2. Similar 
results were obtained with PEDSV.15 (data not shown). 
These results suggest that the involvement of the actin and the microtubule 
cytoskeleton depends on both viral tropism and the vascular bed origin of the cells. 
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Fig. 16: Involvement of the actin cytoskeleton in entry into hEC and pEC of the 
endotheliotropic TB40/E and the fibrotropic TB40/F HCMV strains. hEC and pEC were 
pretreated for 1 hour with a specific inhibitor of actin polymerization before being inoculated 
with (A) TB40/E or (B) TB40/F. Results are expressed as the percentage of inhibition of 
infection relative to untreated cells, and bars represent mean values ± SD of three independent 
experiments. Comparisons were performed using t test and significant differences are 
indicated as follow: *: < 0.05, ****: <0.0001. The mean of three independent experiments is 
shown. (C) Effect of cytochalasin D on fibrous actin organization. 2A2 were exposed to 
cytochalasin D for 1 hour, fixed and stained with rhodamine–phalloidin. 
 
 
 
 
Fig. 17: Involvement of the microtubule cytoskeleton in entry into hEC and pEC of the 
endotheliotropic TB40/E and the fibrotropic TB40/F HCMV strains. hEC and pEC were 
pretreated for 1 hour with a specific inhibitor of microtubule polymerization before being 
inoculated with (A) TB40/E or (B) TB40/F. Results are expressed as the percentage of 
inhibition of infection relative to untreated cells, and bars represent mean values ± SD of 
three independent experiments. Comparisons were performed using t test and significant 
differences are indicated as follow: *: < 0.05, **: <0.01. The mean of three independent 
experiments is shown. (C) Effect of nocodazole on microtubules organization. 2A2 were 
exposed to nocodazole for 1 hour, fixed and stained for tubulin. 
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6.3 Involvement of the host species in HCMV translocation and 
initiation of replication 
6.3.1 Assessment of the role of the classical endolysosomal pathway 
in HCMV intracellular trafficking to the nucleus 
Subsequent to internalization, viral particles are transported from the cell 
surface to the nucleus where the viral genome is released, allowing initiation of viral 
replication. The classical endolysosomal pathway is responsible for transport of cargo 
in endocytic vesicles in the cytoplasm. Viral particles contained in endocytic vesicles 
are delivered to early endosomes containing the early endosome antigen 1 (EEA1) 
(194) and are subsequently transferred to late endosomes and lysosomes expressing 
lysosome-associated membrane protein 2 (LAMP2) (39). Thus, I investigated whether 
TB40/E (Fig. 18) and TB40/F (Fig.19), once internalized in endocytic vesicles, use 
the classical endolysosomal pathway to traffic further into the cytoplasm. To assess 
this, I examined by confocal microscopy the co-localization of the HCMV viral 
glycoprotein B (gB) with the early endosomal marker EEA1 and the late endosomal 
marker LAMP2 at different intervals after infection (10, 30, 60 and 90 mpi). I 
reasoned that since both viral strains used endocytic pathways to enter hEC and pEC, 
gB will still be on the viral envelope and therefore still associated with viral particles 
in endocytic vesicles. Co-localization is expressed as Pearson’s coefficient (which 
correlates the pixel intensity from the different fluorochromes) represented by values 
comprised between -1 and 1 and which can be interpreted as follows: the higher the 
coefficient is, the more two markers co-localize. After infection of hEC with TB40/E, 
co-localization of gB with EEA1 increased with time to reach a peak at 60 mpi 
followed then by a diminution of Pearson’s coefficient reflecting a decreasing co-
localization. Similar results were observed for pEC, however the peak was reached 
earlier than in hEC (30 mpi). This observation suggests that transport and / or 
internalization occurs faster in pEC compared to hEC (Fig. 18A). In Figure 18B, a 
representative image for co-localization between gB and EEA1 (green) is shown and 
is characterized in the merged image as a yellow staining. A similar scheme was 
observed for the co-localization of gB with LAMP2 in 2A2 cells, HAEC and 
HMVEC (Fig 18C). In PEDSV.15 cells, no LAMP2 was detected, suggesting an 
absence of the protein, which prevented the co-localization analysis. Figure 18D 
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illustrates a representative image for co-localization of gB and LAMP2 in TB40/E-
infected 2A2 cells. 
After infection of hEC with TB40/F, co-localization with EEA1 increased 
continuously until 90 mpi. In contrast, in pEC the Pearson’s coefficient increased and 
reached a peak at 30 mpi and then decreased (Fig. 19A). No modulation of co-
localization was observed between gB and LAMP2 in hEC, suggesting that TB40/F 
does not localize in late endosomes. In 2A2 cells, co-localization of gB with LAMP2 
reached a peak at 30 mpi and then decreased (Fig. 19C). Figures 19 B and D show 
representative images for co-localization of gB with EEA1 and LAMP2 (both green) 
in TB40/F-infected 2A2 cells, respectively. 
These results suggest that both strains use the classical endolysosomal 
pathway to traffic further into the cytoplasm of infected EC and TB40/E trafficking 
occurs faster in pEC compared to hEC. These results also suggest that in hEC, 
TB40/F might be sequestered in early endosomes, which is in accordance with the 
literature showing that viral particles of fibrotropic HCMV strains do not translocate 
to the nucleus of infected hEC. This result would then suggest that the transfer from 
early endosomes to late endosomes is the limiting step for fibrotropic HCMV strains 
nuclear translocation in hEC. 
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Fig. 18: Co-localization between TB40/E gB and components of the classical 
endolysosomal pathway. hEC and pEC were infected with TB40/E for different periods of 
time. (A, C) Co-localization analysis between gB and (A) EEA1 or (C) LAMP2 and 
expressed as Pearson’s coefficient which correlates pixel intensity. (B, D) The pictures show 
a representative staining of (B) EEA1 or (D) LAMP2 with gB in 2A2 cells. For (A) and (C), 
one representative experiment out of three independent experiments is shown, bars represent 
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mean values ± SD and comparisons were performed using t test and significant differences 
are indicated as follow: *: < 0.05, **: <0.01, ***: <0.001, ****: <0.0001. 
 
Fig. 19: Co-localization between TB40/F gB and components of the classical 
endolysosomal pathway. hEC and pEC were infected with TB40/F for different periods of 
time. (A, C) Co-localization analysis between gB and (A) EEA1 or (C) LAMP2 and 
expressed as Pearson’s coefficient which correlates pixel intensity. (B, D) The pictures show 
a representative staining of (B) EEA1 or (D) LAMP2 with gB in 2A2 cells. For (A) and (C), 
one representative experiment out of three independent experiments is shown, bars represent 
Results 
77 
mean values ± SD and comparisons were performed using t test and significant differences 
are indicated as follow: *: <0.05, **: <0.01, ***: <0.001, ****: <0.0001. 
Table 4: Table recapitulating the results of colocalisation of viral particles with markers of 
the endolysosomal pathway. 
 
TB40/E 
 2A2 PEDSV.15 HMVEC HAEC 
EEA1 yes yes yes yes 
LAMP2 yes no staining yes yes 
 
TB40/F 
 2A2 PEDSV.15 HMVEC HAEC 
EEA1 yes yes yes yes 
LAMP2 yes no staining NO NO 
 
 
6.3.2 Role of host species in HCMV nuclear translocation 
Nuclear translocation is the last step of entry preceding the initiation of viral 
replication with the expression of IE proteins. Following internalization of the viral 
particle and release of viral capsids in the cytoplasm, capsids translocate to the 
nucleus and viral tegument proteins, among them pp65, are released in the nucleus. I 
assessed whether nuclear translocation of HCMV occurs in a similar manner in hEC 
and pEC by localizing and measuring pp65 of both TB40/E and TB40/F. hEC and 
pEC were infected at an MOI of 1 and the nuclear localisation of pp65 was analysed 
at different times post-infection (1-24 hpi) by immunofluorescence. As expected, no 
nuclear accumulation of pp65 was observed in TB40/F-infected hEC which is in 
accordance with previous reports showing that TB40/F and other fibrotropic strains 
are adsorbed and internalized by endothelial cells but fails to translocate to the 
nucleus and as a consequence cannot start viral gene expression (265). In contrast to 
hEC, shortly after inoculation (3hpi), pp65 displayed a nuclear localisation in 
TB40/F-infected 2A2 cells and to a lesser extend in TB40/F-infected PEDSV.15 cells. 
More surprisingly, no nuclear accumulation was observed in TB40/E-infected hEC as 
well as pEC (Fig. 20). As a control for infection, EC were stained for IE proteins and 
the expression was analysed 24hpi. In TB40/E-infected EC, IE proteins were 
detected; demonstrating that viral capsids reached the nucleus and viral replication 
had indeed started.  
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Fig. 20: Nuclear accumulation of pp65 in TB40/E- and TB40/F-infected EC. EC were 
infected with TB40/E (A) or TB40/F (B) at an MOI of 1 and the viral tegument protein pp65 
was detected by immunofluorescence. As a control, EC were assessed for the expression of IE 
proteins. Pink staining: Evans Blue cytoplasmic staining, green staining: pp65 or IE as 
indicated. One representative experiment out of three is shown. 
 
The absence of pp65 in the nucleus of TB40/E-infected EC could be explained 
by two hypotheses. The first suggestion would be a reduced expression of pp65 in 
TB40/E viral particles, which would result in a diminished nuclear accumulation that 
cannot be detected by immunofluorescence. To test this possibility, hEC and pEC 
were infected with TB40/E or TB40/F for different periods of times (1 to 24hpi) and 
the accumulation of pp65 was analysed in total extracts by Western blot. pp65 
accumulation was observed in all TB40/F-infected EC and to a lesser extend in 
TB40/E-infected EC. In TB40/E-infected 2A2 cells and HAEC, accumulation was 
detected from 1 hpi to 5 hpi. In TB40/E-infected PEDSV.15 cells and HMVEC, pp65 
was detected from 1 hpi to 3 hpi but the accumulation was weaker than in 2A2 cells 
and HAEC. In TB40/F-infected EC, the accumulation of pp65 was stronger compared 
to the same EC infected with TB40/E. The accumulation started at 1 hpi for all the 
four cell types. Depending on the cell type, the quantity of pp65 detected decreased at 
8 hpi (2A2 cells and HAEC) or 5 hpi (PEDSV.15 cells and HMVEC), suggesting that 
the incoming pp65 might be first degraded (but is then produced later in the 
replication cycle, i.e. 72 hpi (data not shown)). Although the quantity of pp65 differs 
from one cell type to another, the pattern remains: the accumulation of pp65 is higher 
in TB40/F-infected EC compared to TB40/E-infected EC (Fig. 21).  
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Fig. 21: Comparison of accumulation of pp65 in TB40/E- and TB40/F-infected EC. EC 
were infected with TB40/E or TB40/F at an MOI of 1 and the accumulation of the viral 
tegument protein pp65 was detected by Western blot at different times post infection (1 to 24 
hpi). β-actin was used as a loading control. 
 
The second hypothesis would be that both strains have the same amount of 
pp65 in the particles but more TB40/F viral particles would enter EC compared to 
TB40/E viral particles, which would result in higher pp65 accumulation in the cells. 
In accordance with this hypothesis, we previously demonstrated that, contrary to 
HCMV infection of hEC, pEC are more susceptible to infection with TB40/F than 
TB40/E (185). In order to assess whether this discrepancy was due to differential 
entry efficiency between the two HCMV strains, hEC and pEC were infected with 
either TB40/E or TB40/F at an MOI of 1, and at different times post-infection, viral 
DNA was quantified by real-time PCR. In order to eliminate as much bound but not 
internalized virus as possible, cells were extensively washed, trypsinized for 5 
minutes and again extensively washed; nevertheless, we cannot exclude that some 
viral particles still remained attached to the EC. Internalized viral DNA increased 
with time and in both pEC, 2A2 cells and PEDSV.15 cells, the quantity of viral DNA 
was more important in TB40/F-infected cells compared to TB40/E-infected cells. 
Concerning hEC, similar results were observed for HAEC and HMVEC (Fig. 22). 
When comparing hEC and pEC, more viral DNA was detected in pEC compared to 
hEC. In TB40/F-infected 2A2 cells and PEDSV.15 cells, 3 and 1.5 times more viral 
DNA was detected compared to HMVEC and HAEC, respectively and 3 times more 
viral DNA was detected in TB40/E-infected pEC compared to TB40/E-infected hEC. 
These results suggest that i) HCMV internalization into pEC might occur faster than 
pp65 
pp65 
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into hEC and ii) more TB40/F viral particles are internalized into hEC and pEC 
compared to TB40/E viral particles, which could explain the higher accumulation of 
pp65 in TB40/F-infected compared to TB40/E-infected EC. 
As a comparison, I repeated the identical experiment with the same time 
course in MRC-5, which are the cell type usually used for virus propagation. These 
cells are highly susceptible to HCMV infection, and in contrast to hEC, MRC-5 are 
more susceptible to fibrotropic strains compared to endotheliotropic strains. For 
instance, in our hands, in order to produce the same amount of virus, the inoculum of 
TB40/E needs to be increased by two times as compared to TB40/F. Interestingly, at 
30 mpi, almost no viral DNA was detected in TB40/F-infected MRC-5 (mean of 52 
HCMV DNA copies / 30ng of total DNA) compared to TB40/E-infected MRC-5 
(mean of 4227 HCMV DNA copies / 30ng of total DNA). However, later during 
infection, as for hEC and pEC, more viral DNA was detected in TB40/F- compared to 
TB40/E-infected MRC-5 (Fig. 22). This result suggests that after 30 mpi, TB40/F also 
is internalized by fibroblasts faster than TB40/E. It is to be noted that in MRC-5, in 
average >10 and 30 times more viral DNA is detected in comparison to the amount of 
viral DNA sensed in pEC and hEC, respectively. 
To be sure that the internalization discrepancy observed between these two 
strains was not due to a difference of the overall viral input, I quantified the amount of 
viral DNA in the inputs of TB40/F and TB40/E and no significant differences were 
observed (Fig. 22). 
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Fig. 22: Comparison of the quantity of viral DNA internalized into hEC, pEC and 
human fibroblasts after infection with TB40/E or TB40/F. hEC, pEC and human 
fibroblasts (MRC-5) were infected with either TB40/E or TB40/F (MOI of 1) for different 
periods of time. Total DNA was purified, amplified by real-time PCR and viral DNA was 
quantified. Each reaction was done in duplicate, and each point represents the average +/- 
standard deviation of one representative experiment out of three. For MRC-5, each reaction 
was done in duplicate, and the mean of two independent experiments is shown. For the input, 
each reaction was done in duplicate, and one representative experiment out of two is shown. 
White bars: TB40/E, black bar: TB40/F. 
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6.3.3 Effect of pp65 translocation on the initiation of HCMV 
replication 
A previous study demonstrated that the absence of pp65 in the viral genome 
led to a delay in the expression of viral IE genes (291). I thus assessed whether the 
differences observed in pp65 nuclear accumulation could also impact the initiation of 
HCMV replication in pEC. Cells were inoculated with TB40/E or TB40/F and at 
different time post-infection (1 to 24 hpi) IE expression was assessed by Western blot. 
Shortly after infection (5-8 hpi), TB40/E-infected hEC and PEDSV.15 cells displayed 
similar amount of IE proteins, in contrast to 2A2 cells which showed a stronger 
expression, which is in accordance with previous results obtained in the laboratory 
demonstrating that 2A2 cells are more susceptible to HCMV infection (regarding IE 
protein expression) compared to PEDSV.15 cells, HAEC and HMVEC (185)). As 
expected, at 24hpi, almost no IE was detected in TB40/F-infected hEC, which is due 
to the incapacity of fibrotropic strains to replicate in hEC (265). In contrast, both 
types of TB40/F-infected pEC displayed a strong and early expression of IE proteins 
compared to TB40E-infected pEC (Fig. 23), suggesting that pp65 nuclear 
translocation is correlated to the initiation of the expression of IE proteins in pEC. 
 
 
Fig. 23: Time course of infection in TB40/E- compared to TB40/F-infected EC. EC were 
infected with TB40/E or TB40/F at an MOI of 1 and the expression of IE viral proteins was 
detected by Western blot at different times post infection (1 to 24 hpi). The membranes from 
Fig. 20 were stripped and then stained with an anti-IE proteins antibody. β-actin was used as a 
loading control. 
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6.3.4 Involvement of Focal Adhesion Kinase in HCMV 
translocation into human EC 
As described above, it has been documented that fibrotropic strains of HCMV 
do not translocate to the nucleus of hEC and therefore cannot replicate in these cells. 
It has been reported that the activation of Focal Adhesion Kinase (FAK) is important 
for entry and nuclear translocation of Kaposi’s Sarcoma Associated Herpesvirus (152) 
and Herpes Simplex 1 virus into fibroblasts (42). FAK is expressed by most cells and 
is phosphorylated in response to integrin engagement and growth factor stimulation 
(reviewed in (112)). I and others have demonstrated that integrins are involved in 
HCMV entry into hEC, therefore I investigated whether FAK activation (i.e. its 
phosphorylated form) is involved in HCMV nuclear translocation and whether its 
phosphorylation pattern varies between a productive infection (TB40/E) compared to 
an abortive infection (TB40/F). In this results section, work was focused only on hEC 
since no porcine antibodies reactive against phosphorylated form of FAK are 
commercially available. HAEC and HMVEC were infected with either TB40/E or 
TB40/F at an MOI of 3 and the phosphorylation state of FAK was assessed at 
different times post-infection (10, 30 and 60 mpi) by Western blot. As a positive 
control, hEC were stimulated with growth factor. No differences were observed in the 
phosphorylation state of FAK between TB40/E- and TB40/F-infected hEC nor in the 
positive control, suggesting that the culture conditions used were not optimal for this 
study (Fig. 24). Several other positive controls were tested in an attempt to stimulate 
phosphorylation, however none of the different conditions induced a significant 
increase in FAK phosphorylation (data not shown). Unfortunately, the culture 
conditions did not allow us to demonstrate any involvement of FAK in HCMV entry 
into hEC so far. 
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Fig. 24: Comparison of the phosphorylation pattern of FAK in human endothelial 
cells after infection with TB40/E or TB40/F. HAEC and HMVEC were infected with 
either TB40/E or TB40/F at an MOI of 3 for different times (10, 30 and 60 mpi) and the 
activation state of FAK (P-FAK) was assessed by Western blot. β-actin was used as a loading 
control. P-FAK: Phosphorylated form of FAK, +: positive control (20% FCS for 5 min). One 
representative experiment out of four is shown. 
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7 Discussion 
The goal of this thesis was to address how HCMV enters cells from its own or 
from a different species and whether the viral strain tropism influences the entry 
mechanism. Degré et al. showed that pEC cells are susceptible to HCMV infection 
and our group expanded these findings and demonstrated that viral strain tropism and 
the vascular origin of pEC impact on the target cell susceptibility. This discrepancy in 
the efficiency of infection led us hypothesize that entry mechanisms used by HCMV 
depends on both the viral strain tropism and the vascular origin of target cells. For this 
purpose, we compared potential HCMV entry pathways of an endotheliotropic 
(TB/40E) and a fibrotropic (TB40/F) strain in pEC versus hEC. This work focused 
mainly on endothelial cells since i) they are a natural site of HCMV primary infection 
and ii) due to their localization (interface between the graft and the immune system), 
they play an important role in infectious events involved in graft rejection. 
7.1 Role of known human entry cellular receptors in HCMV entry 
into pEC 
To enter human cells, HCMV requires different receptors (PDGFRα and 
EGFR) (34, 272, 308), although not necessary for all settings (131, 301), and co-
receptors (β1, αV and β3 integrin subunits) (81, 307). I showed that except for EGFR 
that is detected only in 2A2 cells, the expression of PDGFRα and the different 
integrin subunits is common to all four cell types used in this study. To test the 
involvement of PDGFRα and integrins in HCMV entry into pEC and hEC, I 
evaluated the consequences of silencing of these receptors / co-receptors on HCMV 
entry. Because of technical issues, I could only assess the involvement of β1 integrins 
and PDGFRα in HCMV entry into hEC and pEC, and we demonstrated that the 
involvement of these two cellular receptors depends on both the species origin and the 
viral tropism. The silencing of PDGFRα reduced the expression of IE proteins 24 hpi 
in pEC but not in hEC. One explanation for this discrepancy would reside in the 
amount of PDGFRα in the target cells. The Western blot analysis revealed that both 
hEC display a weaker expression of this receptor when compared to pEC, which 
would suggest that PDGFRα is dispensable for HCMV entry into HAEC and 
HMVEC as affirmed by Vanarsdall et al. (301). In this study I only used pEC from 
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microvascluar and aortic origin (2A2 and PEDSV.15 cells, respectively), so we 
cannot exclude that PDGFRα might not be involved in HCMV entry into other 
porcine cells as it has been observed with different human cell types. 
In contrast to PDGFRα, silencing of β1 integrins resulted in a reduced 
expression of IE proteins 24 hpi in hEC. Similar results were observed for PEDSV.15 
cells. On the contrary, β1 integrin subunit silencing had no effect on HCMV entry 
into 2A2 cells. One reason for this inconsistency could be that the weaker silencing of 
β1 integrins in 2A2 cells might not be sufficient to interfere with HCMV entry into 
these cells, especially as 2A2 cells are more susceptible to HCMV infection compared 
to all the other cells used in this study (185). Besides, regarding 2A2 cells, one cannot 
exclude that the presence of EGFR on this cell type might as well play a major role in 
HCMV entry. 
In conclusion, as for hEC, entry of both HCMV strains depends on the 
expression of β1 integrins on pEC (except for TB40/F and 2A2 cells). In contrast, 
entry of both strains depends on the expression of PDGFRα on pEC whereas entry 
appears to be PDGFRα-independent for hEC. 
7.2 Involvement of endocytic pathways, lipid rafts and endosomal 
pH in HCMV entry 
Enveloped viruses can use two distinct mechanisms to enter their target cells: 
via direct fusion of the viral envelope with the plasma membrane (example: HIV) and 
via fusion of the viral envelope with the endosomal membrane (example: Hepatitis C 
virus). Depending on the cell type, herpesviruses can use these two mechanisms. 
HSV-1 enters epithelial cells by endocytosis (205) but enters Vero and Hep2 cells by 
direct fusion at the membrane (85-87, 316). The literature has shown that HCMV can 
as well use these two mechanisms depending on the target cell: in fibroblasts, HCMV 
enters by direct fusion with the plasma membrane (54) whereas in epithelial and 
endothelial cells HCMV uses endocytosis (19, 238). To analyse which endocytic 
pathway HCMV uses to enter pEC, I assessed the effect of several inhibitors specific 
for the different endocytic pathways on the entry of TB40/F and TB40/E. When 
TB40/E-infected EC were pre-treated with inhibitors of dynamin-2, clathrin mediated 
endocytosis or macropinocytosis, the expression of IE proteins was inhibited at 8 hpi, 
suggesting that entry of TB40/E into pEC is similar to entry into hEC, i.e. entry 
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occurs in a dynamin-2 dependent mechanism and macropinocytosis, although 
macropinocytosis seemed to be less involved in entry into PEDSV.15 cells as 
compared to 2A2 cells. In contrast, when TB40/F-infected EC were pre-treated with 
the same inhibitors, a reduced IE expression was observed mainly when dynamin-2 
was inhibited, which suggests that entry of TB40/F into pEC occurred mainly by a 
dynamin-2 dependent mechanism, which has yet to be identified. These results 
demonstrate that TB40/E and TB40/F use distinct mechanisms to enter their target 
cells. Recent studies showed that herpesviruses can also use another dynamin-2 
dependent entry mechanism: phagocytosis (48, 100, 295). Since inhibition of 
macropinocytosis has a limited effect on TB40/F entry into pEC, phagocytosis may be 
the more prominent entry mechanism of TB40/F. In order to verify this hypothesis, I 
am currently investigating the effect of an inhibitor of phagocytosis on TB40/F entry 
into pEC. 
The next step was to assess whether lipid rafts, which are detergent insoluble 
plasma membrane microdomains involved in endocytic processes and signalling, play 
a role in HCMV entry into hEC and pEC. It has been demonstrated that several 
viruses use these microdomains to enter their target cells, amongst them HCMV (139, 
307), HSV-1 (15) and the Picornaviridae member echovirus 1 (219). In contrast, the 
human Papillomavirus type 16 (246) and KSHV (227) do not seem to require lipid 
rafts to enter their target cells. For this purpose, I used a drug that disrupts lipid rafts 
and I analysed its effect on entry of both strains in hEC and pEC. The results showed 
that disruption of lipid rafts inhibited IE protein expression at 8 hpi in TB40/E - but 
not TB40/F-infected EC, which demonstrates that entry of TB40/E into EC depends 
on the presence of lipid rafts whereas entry of TB40/F into pEC does not depend on 
the presence of such microdomains. My finding suggests that the viral tropism might 
influence the dependency of lipid rafts of HCMV to enter cells of its own or another 
species. 
Finally, it is known that viruses gain access into the host cells in a pH-
independent mechanism by direct fusion at the plasma membrane or after fusion with 
the endocytic vesicle following exposition to low pH. A novel entry pathway 
involving an endocytic-dependent, pH-independent fusion has been described for 
HSV entry into murine melanoma cells (187), adding a new entry pathway to the 
endocytic pH-dependent and fusion pH-independent mechanisms (85-87, 205). 
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Regarding HCMV, Sinzger et al. demonstrated that TB40/E entry into human 
umbilical vein endothelial cells (HUVEC) occurs by endocytosis in a pH-independent 
manner (262), adding still another mechanism to the first two listed above. In order to 
determine the involvement of endosomal pH acidification in entry of both strains in 
hEC and pEC, I used an inhibitor of endosomal pH acidification and assessed its 
effect on infection. My study clearly demonstrated that TB40/E entry into hEC and 
pEC is pH-dependent, which was associated with an inhibition of IE protein 
expression 8 hpi, whereas a low pH is not a requirement for TB40/F entry into 2A2 
cells and to a lesser extent entry into PEDSV.15 cells, associated with a lower 
inhibition of IE protein expression. These findings demonstrate that involvement of 
the endosomal pH acidification in HCMV entry depends as well on both the vascular 
bed origin of target cells and viral strains.  
In conclusion, TB40/E entry mechanisms are conserved in a normal versus a 
cross species infection and is dependent on dynamin-2, pH and lipid rafts. In contrast, 
the entry mechanisms of TB40/F into pEC differ from the entry mechanism of 
TB40/E in the fact that these mechanisms are independent on pH and lipid rafts. 
7.3 Involvement of cellular cytoskeleton in HCMV internalization 
and translocation 
The cellular cytoskeleton is composed of three different components, namely 
microtubules, actin microfilaments and intermediate filaments (IF). In order to assess 
the involvement of microfilaments and microtubule cytoskeleton in HCMV strains 
entry into hEC and pEC, I used inhibitors of actin and microtubules polymerization 
and analysed their effect on HCMV infection. My results are in accordance with 
literature reporting that actin and microtubule cytoskeletons are required for HCMV 
entry into human cells (19) and nuclear translocation of the viral capsid (207), 
respectively. In pEC, I demonstrated that the actin cytoskeleton is more prominent for 
TB40/E entry into 2A2 cells whereas for PEDSV.15 cells, the microtubule 
cytoskeleton is more important. It was reported that another herpesvirus, namely 
KSHV, uses either actin or microtubules to infect cells, depending on the target cell 
(105, 202). The pEC used in this study have a different vascular bed origin, which 
could explain the differences observed in the involvement of the cytoskeleton in 
HCMV entry into these cells. Besides the origin of the cell type, the viral strain may 
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also influence the role of the cytoskeleton. Indeed TB40/F does not use actin 
cytoskeleton to enter pEC; and microtubules are not and partially involved in TB40/F 
infection of 2A2 and PEDSV.15 cells, respectively. Since actin microfilaments and 
microtubules are dispensable for TB40/F entry into pEC, another component of the 
cellular cytoskeleton may be involved. Currently little is known about the 
involvement of IF in virus entry, however, in 2009, Miller et al. reported that an intact 
vimentin cytoskeleton (one component of IF) is required for HCMV entry into 
fibroblasts (186), which would suggest that TB40/F could use the same mechanism to 
enter and traffic into pEC. However, inhibitors of microtubules and microfilament 
affect IF organization, therefore one must be cautious in the interpretation of such 
results (224).  
In conclusion, in accordance with the literature, I demonstrated that TB40/E 
internalization and translocation in hEC depends on the actin and the microtubule 
cytoskeleton, respectively, and similar mechanisms occur for PEDSV.15 cells. In 
contrast for 2A2 cells, the microtubule cytoskeleton is less important. For TB40/F, 
contrary to TB40/E, these two cytoskeletons are dispensable for internalization and 
traffic into pEC. 
7.4 Involvement of the host species in HCMV translocation and 
initiation of replication 
After formation, endocytic vesicles traffic further into the cytoplasm and fuse 
with vesicles from the endolysosomal pathway in order to transfer their cargo (for 
instance virions) to more acidic compartments such as early endosomes and 
lysosomes. Besides guiding viral particles to their replication site, the endolysosomal 
pathway provides an appropriate environment to viruses for uncoating and 
nucleocapsid release, which is essential for a productive infection. My results showed 
that early after infection, internalized viral particles locates successively in EEA1+ and 
LAMP2+ compartments, suggesting that HCMV uses the classical endolysosomal 
pathway for intracellular trafficking. In order to better characterize intracellular 
trafficking events, it would be interesting to evaluate the involvement of two 
molecules: Rab5 and Rab7. These two small GTPase are important for vesicular 
traffic through the endolysosomal pathway: Rab5 is important for the delivery to early 
endosomes and Rab7 is essential for the maturation of late endosomes (271). Their 
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involvement can be evaluated with specific SiRNA or with dominant negative 
mutants. The study of the involvement of Rab7 would also confirm the involvement 
of endosomal pH acidification in entry of HCMV. Regarding the results obtained with 
the vacuolar H+-ATPase inhibitor (BafA1), I would think that entry of TB40/E would 
be dependent on Rab7. In contrast, entry of TB40/F into pEC would be independent 
of Rab7, although TB40/F viral particles localize in late endosomes as determined by 
colocalization with LAMP2, which would confirm that late endosome maturation and 
consequently endosomal acidification are not required for TB40/F entry into pEC. 
 
The tegument protein pp65 is an essential structural protein that carries two 
nuclear localization signals (NLS) (91, 248). At very early times after infection (i.e. 1 
hpi) and before the onset of viral gene expression, pp65 originating from the entering 
virus is detected in the nucleus of infected human peripheral blood leukocytes (230) 
and human fibroblasts (11). This rapid nuclear translocation suggests an important 
role of this tegument protein in the initiation of viral gene expression and replication. 
Our laboratory has previously demonstrated that pEC susceptibility to HCMV 
depends on both the vascular bed origin of the cells and viral tropism. All pEC 
demonstrated a higher susceptibility to the fibrotropic strains compared to the 
endotheliotropic strains (185). In the results section, I showed that depending on the 
cell origin (normal versus cross—species infection) and the viral tropism, the entry 
mechanisms diverge. Therefore I then assessed whether nuclear translocation of both 
strains occurs in a similar manner in hEC and pEC. For this purpose I infected hEC 
and pEC with either TB40/E or TB40/F and at short times post infection, the 
localization of pp65 was assessed by immunofluorescence. pp65 was only detected in 
the nucleus of TB40/F-infected pEC. It is of note that pp65 could be detected in the 
nucleus of TB40/E-infected EC when high MOI were used (data not shown). I then 
demonstrated, by Western blot, that higher amounts of pp65 were detected in TB40/F-
infected EC and PCR analysis showed that more viral DNA is detected in TB40/F-
infected compared to TB40/E-infected EC. Because Taylor et al. showed a delayed 
expression of IE proteins in viral particles lacking pp65 (291), I assessed whether the 
discrepancy observed in the accumulation of pp65 in TB40/E- and TB40/F-infected 
EC would result in a different initiation of expression of IE proteins. My results 
showed that the expression of IE proteins occurs earlier in TB40/F-infected pEC. 
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However, translocation and accumulation of pp65 might not be linked to the initiation 
of IE proteins. Indeed Schmolke et al. demonstrated that pp65 is dispensable for viral 
growth since viral particles lacking pp65 replicates as efficiently as control viral 
particles expressing this tegument protein (249). Besides, Dal Monte et al. showed 
that a reduced expression of pp65 in cells expressing an antisense RNA to UL83 
(gene encoding for pp65) inhibits viral replication. However, they observed that their 
antisense RNA also reduces the expression of pp71, another tegument protein. They 
concluded that the effect they observed was most likely due to the inhibition of pp71 
expression rather than the reduced pp65 expression (62). It has been demonstrated 
that pp71 also localize in the nucleus of infected cells early during infection (122); 
therefore, in my settings, one can think that the higher accumulation of pp65 in 
TB40/F-infected pEC might as well correlates with higher amounts of pp71, which 
would be responsible for earlier IE proteins expression. One possible experiment to 
verify this hypothesis would be to assess the efficiency of initiation of replication of 
TB40/F particles lacking pp71 expression produced from bacterial artificial 
chromosome. 
In conclusion, a marked difference was observed in the translocation of both 
strains in EC from human and porcine origin. The most surprising observation was the 
absence of nuclear accumulation of pp65 tegument protein in TB40/E-infected hEC 
and pEC. In contrast a nuclear accumulation was observed in TB40/F-infected pEC 
which correlates with higher amounts of pp65 accumulation, higher viral DNA copies 
and earlier initiation of replication. These observations are likely due to higher 
amount of pp71 whose expression is correlated to the expression of pp65 since pp71 
can be transcribed as the second open reading frame of a bicistronic mRNA encoding 
for pp65 (235). 
 
Finally I investigated the limiting step for nuclear translocation of TB40/F in 
hEC. Indeed, as already mentioned, fibrotropic strains do not replicate in hEC because 
of the incapacity of such viral particles to translocate in the nucleus of infected hEC 
(265). The literature shows that nuclear translocation of two other herpesviruses, i.e. 
KSHV and HSV-1 and HSV-2, is dependent on the activation of FAK. This kinase, 
located in focal adhesion, participates in the regulation of microtubules function and 
controls the actin cytoskeleton (reviewed in (245)). Therefore I assessed whether FAK 
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is involved in HCMV nuclear translocation and whether the activation of FAK 
depends on HCMV viral tropism. For this purpose I infected hEC with either TB40/E 
or TB40/F for different periods of time and I compared the activation profile of FAK 
in TB40/E- and TB40/F-infected hEC. In my settings I was not able to detect any 
differences neither in the activation profile of TB40/E-, TB40/F-infected hEC nor in 
the positive control. Therefore I was not able to investigate the involvement of FAK 
in HCMV entry into hEC. However, one could speculate that the absence of 
modulation of FAK phosphorylation might be correlated to the absence of a 
relationship between HCMV entry and FAK and the involvement of another kinase, 
maybe related to FAK, which complements some functions of FAK (259): the 
proline-rich tyrosine kinase-2 (Pyk2). Pyk2 and FAK share a similar domain structure 
and common phosphorylation sites. Besides, Pyk2 is highly expressed on EC amongst 
others (288) and its activation is regulated by intracellular calcium (Ca2+) signal (322). 
Nokta et al. demonstrated that shortly after infection (1 hpi), an excessive influx of 
calcium occurs in human fibroblasts (206). It is possible that this Ca2+ influx might 
activate Pyk2 which would consequently facilitate HCMV entry. This alternative 
pathway is involved in KSHV entry into target cells in the absence of FAK (152). 
7.5 Possible strategy for the prevention of HCMV infection of pEC 
Because of the absence of a common entry pathway for all the cell types and 
the viral strains, preventing HCMV infection of pEC by way of cell manipulation will 
be challenging. A more suitable and more efficient approach to impair entry might be 
to aim at the initial entry step common to all cell types and strains, i.e. binding to 
HSPGs. Our laboratory has investigated the protective capacity of low molecular 
weight dextran sulfate (DXS) on EC. Millard et al. investigated the antiviral 
properties of low molecular weight DXS and they demonstrated that DXS prevents 
HCMV infection of pEC in vitro (personal communication). Besides its antiviral 
activity, it has been previously demonstrated that DXS inhibits the complement 
system (Wuillemin, 1953-1960) and the coagulation cascade (Wuillemin, 12913-
12918). In the context of xenotransplantation, it was shown that DXS i) protects pEC 
from NK cells cytotoxicity (Laumonier, 838-843) and ii) delays HAR in a model of 
pig-to-human xenotransplantation by inhibiting the complement cascade (Fiorante, 
24-35). Therefore, pre-treating organs with DXS prior transplantation might be one 
possible strategy to prevent HCMV infection of pEC. 
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8 Conclusion 
My findings demonstrate that HCMV uses distinct entry pathways that are 
dependent on the viral strain, on the species origin and the vascular bed origin of the 
target cells. The remarkable ability of HCMV to enter cells from its own or another 
species and to initiate a productive infection further underlines the impressive 
adaptability of HCMV. As demonstrated by the large array of immune evasion 
mechanisms, HCMV is able to exploit different entry strategies. The dogma of a strict 
species-specificity of herpes viruses needs to be reconsidered. Given that pEC 
infection with HCMV leads to cytopathic effects and increased apoptosis, which most 
likely would lead to vasculopathy, graft damage and graft rejection, prevention of 
such an infection is paramount should experimental xenotransplantation ever reach a 
clinical application. A potential avenue is to render porcine grafts resistant to HCMV 
infection by blocking viral entry and propagation. 
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9.2 Abbreviations 
ACXR: acute cellular xenograft rejection 
AHXR: acute humoral xenograft rejection 
AIDS: acquired immunodeficiency syndrome  
AP: assembly protein 
APC: allophycocyanin 
ART: antiretroviral therapy 
BafA1: bafilomycin A1 
CDV: cidofovir 
CMV: cytomegalovirus 
CPE: cytopathogenic effect 
CVB-5: Coxsackievirus B5 
DAPI: 4’,6-diamidino-2-phenylindole 
DNA: Deoxyribonucleic acid 
Dpi: day post infection 
E: early (HCMV genes) 
EC: endothelial cells 
EEA1: early endosome antigen 1 
EGFR: epidermal growth factor receptor 
EKC: epidemic keratoconjunctivitis 
EMCV: encephalomyocarditis virus 
ER: endoplasmic reticulum 
ERGIC: endoplasmic reticulum Golgi intermediate complex 
FAK: focal adhesion kinase 
FCS: fetal calf serum 
FOS: Foscarnet 
FX: factor X 
gB: glycoprotein B 
GCV: ganciclovir 
hAdV: human adenovirus 
HAEC: human aortic endothelial cells 
HAR: hyper acute rejection 
HBSS: Hank's balanced salt solution 
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HCMV: human cytomegalovirus 
HCV: hepatitis C virus 
hEC: human endothelial cells 
HHV: human herpesvirus 
HIV: human immunodeficiency virus 
HMVEC: human dermal microvascular endothelial cells 
Hpi: hours post infection 
HSPG: heparansulfate proteoglycans 
HSV-1/2: herpes simplex virus 1/2 
HUVEC: human umbilical vein endothelial cells 
HVEM: herpes virus entry mediator 
IBMIR: instant blood-mediated inflammatory reaction 
IE: immediate early 
IF: intermediate filament 
IFN: interferon 
KSHV: Kaposi's sarcoma-associated herpesvirus 
L: late (HCMV genes) 
LAMP2: Lysosome-associated membrane protein 2 
mC-BP: minor capsid protein-binding protein 
MCMV: mouse cytomegalovirus 
MCP: major capsid protein 
mCP: minor capsid protein 
MHC-I: major histocompatibility complex class I 
min: minutes 
MOI: multiplicity of infection 
Mpi: minutes post infection 
MTOC: microtubule-organizing center 
MxA: myxovirus protein A 
ND10: nuclear domain 10 (also referred to as PML) 
NLS:  nuclear localization signal 
pAP: assembly protein precursor 
PBS: phosphate buffered saline 
PCMV: porcine cytomegalovirus 
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PCV: porcine circovirus 
PCVAD: porcine circovirus associated disease 
PCVD: porcine circoviral disease 
PDGFRα: platelet-derived growth factor receptor alpha 
PE: phycoerythrin 
pEC: porcine endothelial cells 
PERV: porcine endogenous retrovirus 
PFA: paraformaldehyde 
PKC: protein kinase C 
PLHV: porcine lymphotropic herpesvirus 
PML: promyelocytic leukaemia nuclear 
PMWS: post weaning multisystemic wasting syndrome 
PRV: pseudorabies 
Pyk2: proline-rich tyrosine kinase-2 
RCMV: rat CMV 
RNA: ribonucleic acid  
SCP: smallest capsid protein 
SiRNA: small interfering RNA 
SPF: specific pathogen free 
T1D: type 1 diabetes 
TBS: Tris-buffered saline 
TGEV: transmissible gastroenteritis coronavirus 
TFPI: tissue factor pathway inhibitor 
UL: unique long sequence 
US: unique short sequence 
VCAM-1: vascular cell adhesion molecule 1 
VGCV: valganciclovir 
vWF: von Willebrand Factor 
XNA: xenoreactive natural antibodies 
αGal: α(l,3)-galactosyltransferase 
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